# BEFORE THE SCIENCE SUBCOMMITTEE

OF THE

## INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE

# CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

#### REGULAR MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: WEDNESDAY, SEPTEMBER 29, 2010

11:30 A.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 88383

#### INDEX

ITEM	DESCRIPTION	PAGE	NO.
CALL TO ORDE	R		3
ROLL CALL			3
OF CHANGES T	SCUSSION OF AND CONSIDERATION OF EXTRAORDINARY PETITION APPEALS PROCESS		4
SCORING OF G ADVOCATE MEM	OF PROPOSAL FOR PROGRAMMATIC GRANT APPLICATIONS BY PATIENT BERS OF GRANTS WORKING GROUP ON IN DISCUSSION AND DECISIONS PPLICATIONS	3	5
USE OF UNUSE GRANT FOUND	ON OF PROCESS FOR APPROVING ED DISEASE TEAM RESEARCH AWARD FUNDS FOR RESEARCH THAT GOES ECOPE OF THE ORIGINAL RFA'S	5	5
PUBLIC COMME	NT	NON	Ε

2

	DARRISTERS REPORTING SERVICE
1	WEDNESDAY, SEPTEMBER 29, 2010
2	11:30 A.M.
3	
4	CHAIRMAN SHEEHY: THANKS, MELISSA. AND I
5	WANT TO THANK EVERYBODY FOR BEING ON THE CALL TODAY.
6	I THINK WE'LL START THE MEETING. DO YOU WANT TO
7	CALL THE ROLL.
8	MS. KING: JACOB LEVIN. MARCY FEIT.
9	MICHAEL FRIEDMAN.
10	DR. FRIEDMAN: HERE.
11	MS. KING: BOB KLEIN.
12	CHAIRMAN KLEIN: HERE.
13	MS. KING: FRANCISCO PRIETO. ED PENHOET.
14	PHIL PIZZO. JEANNIE FONTANA.
15	DR. FONTANA: HERE.
16	MS. KING: DUANE ROTH.
17	MR. ROTH: HERE.
18	MS. KING: JOAN SAMUELSON. JEFF SHEEHY.
19	CHAIRMAN SHEEHY: HERE.
20	MS. KING: OSWALD STEWARD. ART TORRES.
21	MR. TORRES: HERE.
22	CHAIRMAN SHEEHY: WE DON'T HAVE A QUORUM,
23	DO WE?
24	MS. KING: NOT QUITE YET. NO. WE NEED
25	NINE.
	7
	3

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	CHAIRMAN SHEEHY: SO I THINK THE FIRST
2	THING THAT WE'LL LOOK AT IS CHANGES TO THE
3	EXTRAORDINARY PETITION POLICY/APPEALS POLICY. WE
4	HAVE THREE OPTIONS HERE. HAVE PEOPLE HAD AN
5	OPPORTUNITY TO LOOK THROUGH THE OPTIONS THAT I
6	KNOW SOME OF THIS ARRIVED LATE. WE'VE BEEN WORKING
7	ON THIS.
8	OPTION A IS DR. STEWARD'S OPTION,
9	SUGGESTION, AND IT WOULD HAVE THE APPLICANT APPEND
10	THEIR ACTUAL APPLICATION TO THEIR EXTRAORDINARY
11	PETITION.
12	OPTION C OPTION B IS A PROCESS THAT
13	PROVIDES THE BOARD WITH OFFICIAL OPTION WHEN THEY'RE
14	PRESENTED WITH A THORNY SCIENTIFIC ISSUE TO TRY TO
15	GET SOME RESOLUTION ABOUT THAT, THAT ISSUE.
16	AND OPTION C IS A VARIATION ON THAT. AND
17	I THINK AT LEAST HERE WE'VE BEEN WORKING OFF OPTION
18	В.
19	ANY COMMENTS, ANY THOUGHTS FROM ANYONE?
20	IT WOULD BE GREAT IF WE COULD
21	CHAIRMAN KLEIN: IS OS STEWARD ON, JEFF?
22	CHAIRMAN SHEEHY: NOT YET.
23	CHAIRMAN KLEIN: OKAY. I WOULD JUST
24	COMMENT THAT GIVEN THE VARIOUS OPTIONS, I HAD A
25	CHANCE TO TALK TO YOU, JEFF, AND TO TALK TO THE
	4

1	SCIENTIFIC STAFF. AND WE WERE ABLE TO HAVE A
2	DISCUSSION OF THE VARIOUS ISSUES THAT AFFECTED THE
3	EXTRAORDINARY PETITION PROCESS. AND SO SOME TIME
4	HAS BEEN PUT INTO SOME VERY THOUGHTFUL DISCUSSIONS
5	AND PUT INTO THE OPTION THAT IS NOW LABELED WHAT
6	IS OUR CURRENT LABEL? OPTION B. AND THERE WAS
7	SOME VERY IMPORTANT DISCUSSIONS THAT I HAD WITH IAN
8	SWEEDLER ABOUT THE PROBLEMS WITH HAVING AN
9	APPLICATION WHICH IS FILLED WITH PROPRIETARY
10	INFORMATION AND WORKING IT'S A HUGE DISINCENTIVE
11	TO PRIOR COMPANY OR A NONPROFIT SPONSOR TO HAVE TO
12	GO THROUGH AND NEGOTIATE LINE BY LINE ON LONG
13	APPLICATIONS OF WHAT'S PROPRIETARY AND (BREAKUP IN
14	TRANSMISSION).
15	IT IS A DISINCENTIVE FOR THEM TO PUT THEIR
16	BRILLIANT THOUGHTS AND THEIR LIFE'S WORK INTO AN
17	APPLICATION TO US. SO I WOULD HOPE MAYBE WE COULD
18	START WITH OPTION B, BUT I WANT I WOULD WANT TO
19	HEAR FROM OS IF HE WANTED TO START WITH OPTION A.
20	BUT I DO THINK THAT OPTION B DOES NOT HAVE A LOT OF
21	THE LEGAL PROBLEMS AND DISINCENTIVES FOR SCIENTISTS
22	IN THE SYSTEM WHETHER FROM PUBLIC OR PRIVATE SOURCES
23	THAT OPTION A HAS.
24	MR. HARRISON: COULD I JUST ADD ONE
25	ADDITIONAL COMMENT ABOUT OPTION A?

1	CHAIRMAN KLEIN: WHO JUST JOINED?
2	CHAIRMAN SHEEHY: GO AHEAD, JAMES.
3	MS. SAMUELSON: JEFF, JOAN HERE.
4	MR. HARRISON: THE ISSUE YOU HIGHLIGHTED
5	IS AN IMPORTANT ONE. AND IAN, I KNOW, CAN CONFIRM.
6	OFTENTIMES WHEN WE GET A PUBLIC RECORDS ACT REQUEST,
7	IT WILL TAKE WEEKS, IF NOT A MONTH, TO GO THROUGH
8	THE PROCESS OF IDENTIFYING AND FIGURING OUT WHAT IS
9	PROPRIETARY INFORMATION AND WHAT CAN BE PRODUCED
10	PUBLICLY.
11	ONE OF THE CHALLENGES POSED BY OPTION A IS
12	THAT GIVEN THE VERY LIMITED AMOUNT OF TIME FROM THE
13	TIME AN EXTRAORDINARY PETITION IS FROM THE TIME
14	THE APPLICANT RECEIVES ITS REVIEWS TILL BOARD
15	REVIEW, IT WOULD BE VERY DIFFICULT TO CONCLUDE THOSE
16	DISCUSSIONS OVER WHAT CAN BE REDACTED BEFORE THE
17	EXTRAORDINARY PETITION WOULD HAVE TO BE FILED IN
18	ADVANCE OF THE BOARD MEETING. SO IT'S JUST A
19	PRACTICAL PROBLEM THAT WOULD BE POSED.
20	CHAIRMAN SHEEHY: AND, JOAN, WHERE WE ARE,
21	WE'RE ON ITEM 3, CONSIDERATION OF CHANGES TO THE
22	EXTRAORDINARY PETITION APPEALS PROCESS.
23	MS. SAMUELSON: OKAY.
24	CHAIRMAN SHEEHY: AND WE DID A LITTLE BIT
25	OF DISCUSSION OF OPTION A. I ACTUALLY THINK THAT
	6

1	OPTION B IS WHAT'S OPERATIVE. JAMES, WOULD YOU MIND
2	RUNNING THROUGH THE HIGH POINTS OF OPTION B, AND
3	PERHAPS WE CAN GET A MOTION TO CONSIDER IT. AND
4	EVEN IF WE DON'T HAVE A QUORUM, WE CAN DO A SENSE OF
5	THE COMMITTEE.
6	MR. HARRISON: FIRST OF ALL, I SHOULD MAKE
7	CLEAR THAT ALTHOUGH OPTION B HAS A HEADER THAT
8	SPECIFIES EXTRAORDINARY PETITION PROCESS, AND
9	ALTHOUGH THE DISCUSSION OF THIS PROPOSED POLICY
10	AROSE OUT OF CONCERNS CONCERNING THE EXTRAORDINARY
11	PETITION PROCESS, OPTION B IS NOT LIMITED TO
12	CIRCUMSTANCES IN WHICH AN EXTRAORDINARY PETITION IS
13	FILED. I JUST WANTED TO MAKE SURE THAT IS CLEAR AT
14	THE OUTSET.
15	OPTION B GIVES THE BOARD A TOOL TO USE IN
16	CIRCUMSTANCES WHEN AN APPLICATION IS PRESENTED AND
17	AN ISSUE OF FACTUAL DISPUTE OR A FACTUAL QUESTION
18	ARISES AT THE BOARD THAT CAN'T BE RESOLVED DURING
19	THE BOARD MEETING ITSELF. AND UNDER THOSE VERY
20	LIMITED CIRCUMSTANCES, OPTION B WOULD GIVE THE BOARD
21	THE AUTHORITY TO CONDITIONALLY DENY THE APPLICATION
22	TO GIVE THE BOARD TIME TO OBTAIN THE ADDITIONAL
23	INFORMATION THAT IT NEEDS TO RESOLVE THE FACTUAL
24	ISSUE.
25	THIS WOULDN'T BE INTENDED TO BE USED FOR
	7

1	PROGRAMMATIC QUESTIONS. THE INTENT WOULD BE TO
2	LIMIT THIS TO ISSUES OF SCIENTIFIC FACT THAT ARISE
3	DURING THE REVIEW OF AN APPLICATION. OPTION B
4	CREATES A BIFURCATED PROCESS. IF THE FACTUAL ISSUE
5	THAT IS IDENTIFIED BY THE BOARD IS A FAIRLY
6	STRAIGHTFORWARD ONE THAT CAN BE ANSWERED THROUGH
7	RESEARCH BY STAFF OR BY THE ADMINISTRATIVE CHAIR OF
8	THE WORKING GROUP OR THE ACTING CHAIR, THEN THE
9	ISSUE WOULD BE REFERRED TO THE ADMINISTRATIVE CHAIR
LO	AND THE ACTING CHAIR OF THE GROUP, WHO WOULD EITHER
L1	CONDUCT THE RESEARCH THEMSELVES OR ASK STAFF TO DO
L2	IT AND WHO WOULD THEN REACH DISCUSS THE MATTER
L3	AND DETERMINE WHETHER OR NOT IN THEIR VIEW THE NEW
L4	INFORMATION WARRANTS RECONSIDERATION OF THE BOARD'S
L5	DECISION TO CONDITIONALLY DENY FUNDING FOR THE
L6	APPLICATION.
L7	AND THAT DETERMINATION, IF THEY CONCUR,
L8	WOULD THEN GO TO THE BOARD FOR ITS REVIEW.
L9	MS. BAUM: CAN I HAVE TWO POINTS OF
20	CLARIFICATION? JUST SO WHEN WE'RE READING BACK,
21	WHAT WE'RE CONSIDERING TO BE OPTION B ISN'T MARKED
22	AS OPTION B. SO IT HAS A HEADING THAT'S CALLED
23	"EXTRAORDINARY PETITION PROCESS, ADDITIONAL ANALYSIS
24	OPTION." THE TITLE DOES NOT SAY OPTION B. I DON'T
25	WANT THERE TO BE ANY CONFUSION BECAUSE THE OTHER

1	DOCUMENTS HAVE OPTION A AND ANOTHER DOCUMENT IS
2	LABELED OPTION C. SO FOR POINT OF CONFUSION, I
3	THOUGHT THAT WAS IMPORTANT TO NOTE.
4	MS. KING: IT DOES SAY ITEM 3 B AT THE TOP
5	JUST SO PEOPLE KNOW WHAT THEY'RE LOOKING AT.
6	MS. BAUM: I WAS CONFUSED INITIALLY, SO I
7	THOUGHT OTHERS MIGHT BE.
8	AND IT SEEMS TO ME THAT MAYBE THE TERM
9	"STAFF" WOULD REFER TO THE PRESIDENT AND STAFF,
10	POINTS OF CLARIFICATION.
11	MR. TORRES: WHERE DO YOU WANT THAT
12	AMENDMENT?
13	MS. BAUM: I DON'T THINK THERE'S AN
14	AMENDMENT. IT'S JUST I THOUGHT THAT IT SAID THAT IF
15	THERE'S A POINT THAT NEEDS TO BE FURTHER
16	INVESTIGATED, IT COULD BE REFERRED TO STAFF, BUT I
17	THINK IMPLICIT IN THAT, MY UNDERSTANDING IT WAS THE
18	PRESIDENT.
19	MS. KING: AS THE HEAD OF THE STAFF.
20	MR. TORRES: THAT'S NOT A HARD THING TO
21	DO.
22	CHAIRMAN KLEIN: I'D JUST LIKE TO MAKE IT
23	CLEAR THAT WHILE I WORKED ON THIS WITH YOU, JEFF,
24	AND WITH THE STAFF, THAT THIS IS REALLY A CONCEPT
25	THAT YOU CAME UP WITH TO TRY AND ADDRESS KIND OF AN

1	INCOMPLETE PROCESS WE HAD. AND SO IT'S MY PRIVILEGE
2	TO BE IN A SUPPORTING ROLE HERE.
3	CHAIRMAN SHEEHY: THANK YOU. I ACTUALLY
4	WAS HOPING, UNLESS SOMETHING WAS REALLY PERTINENT,
5	THAT JAMES COULD FINISH WITH HIS EXPLA WERE YOU
6	DONE, JAMES?
7	MR. HARRISON: NO.
8	CHAIRMAN SHEEHY: IT'S KIND OF HARD FOR ME
9	TO CHAIR A MEETING IF THERE'S NOT SOME PROCESS
10	WHEREBY I'M ALLOWED TO CONDUCT IT. GO AHEAD, JAMES.
11	MR. HARRISON: JUST TO FINISH THEN, AS I
12	WAS SAYING, THIS PROPOSAL INCLUDES A BIFURCATED
13	OPTION. IF IT'S A SIMPLE, STRAIGHTFORWARD MATTER
14	THAT CAN BE RESOLVED THROUGH INVESTIGATION SUCH AS
15	RESOURCE PUBMED OR SOME OTHER EASILY ATTAINABLE
16	INFORMATION, THEN IT WOULD BE THE ROLE OF THE
17	ADMINISTRATIVE CHAIR AND THE ACTING CHAIR, IF THEY
18	CONCUR, TO DETERMINE WHETHER OR NOT IN THEIR VIEW
19	THE NEW INFORMATION MERITS RECONSIDERATION OF THE
20	BOARD'S DETERMINATION CONDITIONALLY NOT TO FUND THE
21	APPLICATION. IF THEY CONCUR, THEN THAT
22	RECOMMENDATION WOULD GO TO THE BOARD FOR ITS
23	CONSIDERATION.
24	IF THEY DON'T CONCUR OR IF IT'S A MATTER
25	THAT REQUIRES SOME ADDITIONAL ANALYSIS, THE ACTING

1	CHAIR AND THE ADMINISTRATIVE CHAIR WOULD EACH
2	DESIGNATE A MEMBER OF THE GRANTS WORKING GROUP, NOT
3	INCLUDING THE MEMBERS WHO PARTICIPATED IN THE
4	INITIAL REVIEW, AND THOSE FOUR SCIENTISTS WOULD
5	REVIEW THE ISSUE WITH STAFF SUPPORT, IF NECESSARY,
6	AND THEN WOULD MEET ALONG WITH THE TWO VICE CHAIRS
7	OF THE GRANTS WORKING GROUP, THE BOARD CHAIR, AND
8	ANOTHER PATIENT ADVOCATE TO CONSIDER THE SCIENTISTS'
9	REVIEW OF THE INFORMATION AND ULTIMATELY TO CONSIDER
10	A MOTION AS TO WHETHER OR NOT THE NEW INFORMATION OR
11	ANALYSIS PRESENTED IN THEIR VIEW WARRANTS
12	RECONSIDERATION OF THE BOARD'S CONDITIONAL
13	DETERMINATION NOT TO FUND.
14	THAT RECOMMENDATION TOGETHER WITH ANY
15	MINORITY REPORT WOULD THEN GO TO THE BOARD FOR ITS
16	CONSIDERATION. IN ANY CASE THESE RECOMMENDATIONS
17	WOULD BE PLACED ON THE BOARD'S CONSENT CALENDAR AND
18	WOULD BE DISPOSED OF THAT WAY UNLESS A MEMBER OF THE
19	BOARD ASKED FOR THE MATTER TO BE CONSIDERED AS A
20	STANDALONE ITEM ON THE BOARD'S AGENDA.
21	CHAIRMAN SHEEHY: JUST TO BE CLEAR THAT
22	THIS IS TAKING PLACE WITHIN THE CONSTRUCT OF THE
23	GRANTS WORKING GROUP.
24	MR. HARRISON: THAT'S CORRECT. THIS WOULD
25	BE A SUBGROUP OF THE GRANTS WORKING GROUP.

1	CHAIRMAN SHEEHY: AND TO BE CLEAR, THIS
2	IS THE MIDDLE ONE IS TITLED "ITEM 3 B, ADDITIONAL
3	ANALYSIS OPTION." SO DO BOARD MEMBERS HAVE COMMENTS
4	ON THIS?
5	MR. ROTH: CAN YOU HEAR ME OKAY?
6	CHAIRMAN SHEEHY: YES.
7	MR. ROTH: SO THERE ARE PARTS OF THIS I
8	LIKE, BUT I WANT TO ASK A QUESTION AND SEE IF OTHERS
9	HAVE THE SAME CONCERN. I WOULD THINK IF THIS
10	DOESN'T REQUIRE AN EXTRAORDINARY PETITION, THAT WE
11	WOULD EXPECT TO SEE A LOT OF SCIENTISTS WHO WERE
12	DENIED APPROVAL STAND IN FRONT OF US AND MAKE A
13	SCIENTIFIC CASE ON THE SPOT THAT WOULD BE HARD TO
14	REFUTE AT THAT TIME AND, THEREFORE, REALLY CONSUME A
15	LOT OF OUR TIME BY COMING BECAUSE IF YOU DON'T HAVE
16	TO PUT IT DOWN IN WRITING, YOU CAN JUST SHOW UP AND
17	SAY I WANT TO SHOW YOU WHERE THEY MADE THEIR
18	MISTAKE, AND WE GET INTO A SCIENTIFIC DISCUSSION.
19	THEN IT REALLY, I THINK, INVITES THAT KIND
20	OF VERY DIFFICULT SITUATION WE'VE HAD IN THE PAST
21	WHERE WE JUST AREN'T EQUIPPED TO DO IT. BUT THE
22	ATTEMPT TO GET TO THAT IS THE PART I LIKE ABOUT THIS
23	PROPOSAL. THE PROBLEM I SEE IS THAT WITHOUT HAVING
24	TO PUT SOMETHING IN WRITING TO BE CONSIDERED IN
25	ADVANCE, WE'RE KIND OF HAVING TO REACT ON THE SPOT
	12

1	IN A BOARD MEETING.
2	CHAIRMAN SHEEHY: WELL, WE TALKED ABOUT
3	THIS IN PREPARING THIS. AND ONE OF THE DIFFICULTIES
4	WE FACED WAS THAT IF YOU DO REQUIRE AN EXTRAORDINARY
5	PETITION TO DO THIS, THEN YOU'VE BASICALLY INVITED
6	EVERYONE TO SUBMIT AN EXTRAORDINARY PETITION BECAUSE
7	THAT'S THE ONLY WAY THEY MIGHT HAVE AN OPPORTUNITY
8	TO ENTER THIS PROCESS.
9	AND I THINK THE RECORD GIL IS NOT HERE,
10	BUT I THINK THE RECORD IS PRETTY MIXED MAYBE PAT
11	CAN SPEAK TO THAT WITH PEOPLE WHO ARE RIGHT UNDER
12	THE SCORING, RIGHT BELOW THE FUNDABLE RANGE THAT
13	SOME PERCENTAGE DO FILE EXTRAORDINARY PETITIONS, BUT
14	IT'S NOT NECESSARILY ROUTINE. AND THAT IN THE
15	CONTEXT OF DISCUSSING ONE OF THOSE GRANTS THAT A
16	BOARD MEETING MAY MOVE UP FOR PROGRAMMATIC REASONS,
17	A DISEASE THAT IMPACTS THEM, FOR INSTANCE, THERE IS
18	A SCIENTIFIC ISSUE THAT WE CAN'T RESOLVE, IT WOULD
19	BE HELPFUL TO BE ABLE TO GET A LITTLE BIT MORE
20	INSIGHT TO IT EVEN IF THE APPLICANT HAD NOT DECIDED
21	TO FILE AN EXTRAORDINARY PETITION.
22	DR. STEWARD: I'M SORRY TO BE LATE IN
23	JOINING YOU. JUST WANTED TO LET YOU KNOW I'M HERE.
24	DR. LEVIN: JACOB LEVIN FROM UC IRVINE
25	ALSO JOINED A FEW MINUTES AGO.

1	MS. KING: FOR THE RECORD, WE DO HAVE A
2	QUORUM NOW, MR. SHEEHY. GO AHEAD, DR. OLSON.
3	DR. OLSON: SO I WAS JUST GOING TO RESPOND
4	TO MR. SHEEHY'S QUESTION REGARDING THE EXTRAORDINARY
5	PETITION. I THINK IT'S BECOMING A LITTLE BIT
6	MORE IT'S BECOMING MORE COMMON FOR PEOPLE TO FILE
7	IT. IT OBVIOUSLY REFLECTS THE BOARD'S WILLINGNESS
8	TO IMPLEMENT IT AND TO RESPOND TO IT. I THINK THE
9	BOARD, I THINK, HAS BEEN THE BOARD HAS BEEN VERY
10	GOOD ABOUT DETERMINING WHETHER OR NOT THE
11	EXTRAORDINARY PETITION HAS MERIT OR NOT. I DON'T
12	KNOW THAT WE THAT THIS WOULD INCREASE OR DECREASE
13	THE FREQUENCY OF FILING OF THOSE PETITIONS.
14	CHAIRMAN SHEEHY: BOB.
15	CHAIRMAN KLEIN: SO, JEFF, I THINK THIS
16	WAS ACTUALLY A SUGGESTION BY STAFF, BY DR. SAMBRANO,
17	THAT BY NOT LIMITING IT TO EXTRAORDINARY PETITIONS,
18	IT WOULD SERVE TO DISSUADE PEOPLE FROM FILING AN
19	EXTRAORDINARY PETITION. AND I THINK, JEFF, WHAT
20	YOU'VE SAID IN DISCUSSIONS, THIS IS AN OPTION FOR
21	THE BOARD. THIS IS NOT AN OPTION FOR THE CANDIDATE
22	OR APPLICANT. AND SO THIS IS INTENDED REALLY FOR AN
23	EXCEPTION.
24	THE TEXT TRIES TO STRESS THAT IT'S
25	INTENDED THAT THE BOARD RESOLVE EVERYTHING IT
	14

1	POSSIBLY CAN AT THE BOARD MEETING. THIS IS ONLY
2	WHEN THE BOARD CANNOT RESOLVE IT AT THE BOARD
3	MEETING, AND THIS IS NOT AN OPTION FOR AN APPLICANT
4	TO REQUEST SOMETHING LIKE THIS. THIS IS TO BE A
5	REAL EXCEPTION PROCESS WHEN SOMEONE ON THE BOARD
6	FEELS THAT THIS IS SOMETHING WE SHOULD INVESTIGATE
7	AND REQUIRES WORK BEYOND WHAT WE GET IN OUR
8	SCIENTIFIC BRIEFING AT THE BOARD MEETING.
9	SO, DUANE
10	MR. ROTH: JUST TO BE CLEAR, I UNDERSTAND
11	THAT, BUT I DON'T UNDERSTAND WHAT PREVENTS SOMEONE
12	FROM COMING IN THE OPEN SESSION AND MAKING THE
13	COMMENTS THAT THEY HAVE IN THE PAST AND WHY THAT
14	WOULDN'T BE ROUTINE. IF I HAD THIS POLICY RIGHT
15	NOW, I WOULD TRY TO COME IN FRONT OF YOU AND IN
16	THREE MINUTES CREATE DOUBT ABOUT A SCIENTIFIC ISSUE.
17	CHAIRMAN KLEIN: SO IN OUR PROCESS AT THE
18	BOARD, WHEN WE'RE CONSIDERING APPLICATIONS, IF
19	SOMEONE HAS FILED AN EXTRAORDINARY PETITION, THEY
20	HAVE THE RIGHT TO BE HEARD ON THE EXTRAORDINARY
21	PETITION. BUT IN THIS CASE, IF THEY'RE COMING
22	BEFORE THE BOARD AND THIS IS NOT AN ISSUE THAT A
23	BOARD MEMBER HAS RAISED OR THE STAFF HAS RAISED,
24	THEY'RE GOING TO BE IN A POSITION WHERE THE BOARD
25	WOULD NOT BE, FROM WHAT I COULD UNDERSTAND, NOT VERY

1	RECEPTIVE BECAUSE THEY HAVEN'T USED THE PROCESS THAT
2	THE BOARD HAS SET OUT FOR THEM TO USE AS AN
3	EXTRAORDINARY APPEAL.
4	SO IF THEY'RE JUST MAKING AN OFF-THE-HAND
5	COMMENT, IT'S GOING TO BE VERY DIFFICULT FOR THE
6	BOARD TO FOLLOW THAT KIND OF A COMMENT, AND IT WOULD
7	HAVE TO BE A PRETTY UNUSUAL SITUATION. BUT AGAIN,
8	THIS IS A SUGGESTION THAT DR. SAMBRANO HAD. HE
9	THOUGHT THIS WOULD DISSUADE PEOPLE FROM
10	UNNECESSARILY FILING EXTRAORDINARY PETITIONS. IT'S
11	MY EXPECTATION THAT MEANS SOMEONE THIS MIGHT BE A
12	SITUATION WHERE AN UNEXPECTED PROBLEM COMES UP AT
13	THE BOARD MEETING THAT HAS NOT BEEN OTHERWISE
14	PREVIOUSLY COVERED AND IS NOT PART OF THE GRANT
15	REVIEW PROCESS.
16	CHAIRMAN SHEEHY: IF I MIGHT ADD, WE
17	ALREADY HAVE PEOPLE WHO ARE SHOWING UP AND APPEALING
18	TO US. I ACTUALLY THINK THAT IF GRANTEES ARE
19	ANALYZING THE PROCESS, THEY HAVE A MUCH HIGHER
20	CHANCE OF SUCCESS IF THEY IDENTIFY THEIR ISSUES IN
21	ADVANCE OF FILING AN EXTRAORDINARY PETITION. I DO
22	THINK WE NEED TO PUT THIS IN THE CONTEXT OF CHANGES
23	THAT HAVE ALREADY BEEN IMPLEMENTED, WHICH IS THAT
24	STAFF IS NOT ROUTINELY ANALYZING EXTRAORDINARY
25	PETITIONS. THEY'RE ONLY GIVING US FEEDBACK ON THOSE

1	ON WHICH THEY THINK THEY HAVE SOME MERIT.
2	DR. OLSON.
3	DR. OLSON: ACTUALLY THAT'S NOT CORRECT.
4	WHEN THEY'RE FILED WITHIN ADEQUATE TIME, STAFF DOES
5	LOOK AT ALL OF THEM. AND SO, IN FACT, YEAH.
6	MR. SWEEDLER: I THINK ACTUALLY THAT HAD
7	BEEN THE PRACTICE. I THINK THE BOARD RECENTLY
8	REQUESTED THAT STAFF NOT PROVIDE ANY SUBSTANTIVE
9	COMMENTS UNLESS
10	CHAIRMAN SHEEHY: FELT THAT THERE WAS SOME
11	VALUE IN ORDER TO OBVIOUSLY WE WANT TO WE
12	APPRECIATE AND NEED STAFF REVIEW. BUT UNLESS TO
13	SAVE STAFF THE BURDEN OF HAVING TO EXHAUSTIVELY
14	REPLY TO EACH THING, THEY FOUND NO MERIT IN IT, AND
15	ALSO THE BOARD IS NOT TAKING UP EXTRAORDINARY
16	PETITIONS UNLESS A MEMBER OF THE BOARD HAS AN
17	INTEREST IN THE EXTRAORDINARY HAS FOUND SOME
18	MERIT IN IT.
19	I DON'T KNOW. WE COULD POSSIBLY SEE A
20	LINE OF SCIENTISTS TO ARGUE THEIR CASE, BUT
21	HISTORICALLY YOUR BEST BET IS AT THE BOARD WHEN YOUR
22	GRANT IS FIRST PRESENTED. ONCE YOU TAKE THE
23	SCIENTIST OUT OF THE ROOM, THE ACTUAL FACTS OF THE
24	CASE, WHETHER IT WAS BROUGHT UP IN EXTRAORDINARY
25	PETITION OR BY SOMEONE AT A BOARD MEETING, IT'S

1	GOING TO BE THE FACTS. AND WE'RE GOING TO START
2	WORKING THROUGH THE SCIENCE OTHERWISE.
3	I THINK GOING BACK TO THE ADMINISTRATIVE
4	AND THE ACTING CHAIR OF THAT SESSION, THAT THEY'RE
5	GOING TO TAKE A FAIRLY HARD LOOK AT IT. AND IF
6	THERE REALLY IS SOMETHING THERE THAT NEEDS TO BE
7	DISCOVERED, THEN WE HAVE THIS LARGER PROCESS TO
8	REALLY LOOK INTO THE SCIENTIFIC ISSUE.
9	BUT I DON'T WE ALREADY HAVE PEOPLE
10	COMING IN AND SENDING EXTRAORDINARY PETITIONS. I
11	THINK THIS MIGHT END UP BEING A PROCESS THAT MIGHT
12	REDUCE SOME OF THAT AS OPPOSED TO LEADING TO A
13	LARGER SET OF EXTRAORDINARY PETITIONS AND
14	PETITIONERS COMING TO THE BOARD.
15	I'D BE HAPPY TO HEAR OTHER COMMENTS.
16	MR. ROTH: I'D JUST LIKE TO FINISH BY
17	ASKING WHAT IS THE PROCESS IF YOU DON'T FILE AN
18	EXTRAORDINARY PETITION TO ASK FOR THIS REREVIEW?
19	JUST THE BOARD?
20	CHAIRMAN SHEEHY: IT'S SOLELY AT THE
21	DISCRETION OF THE BOARD. SO EVEN IF YOU FILE AN
22	EXTRAORDINARY PETITION, YOU DON'T ACCESS THIS. EVEN
23	IF YOU COME BEFORE THE BOARD AND MAKE PUBLIC COMMENT
24	IN SUPPORT OF AN APPLICATION, YOU DON'T ACCESS THIS.
25	THIS IS AN ACTION BY THE BOARD IF WE'VE SEEN SOME

1	OF THESE CASES WHERE WE HAVE A SUBSTANTIAL
2	PERCENTAGE OF THE BOARD THAT FEELS COMFORTABLE WITH
3	APPROVING AN APPLICATION, A SUBSTANTIAL PROPORTION
4	OF THE BOARD THAT DOESN'T FEEL COMFORTABLE, THERE'S
5	A SCIENTIFIC ISSUE, OR AN EMOTIONAL CONTEXT TO THE
6	CASE, TO THE ISSUE, TO THE APPLICATION, AND THE
7	BOARD SPENDS A LOT OF TIME KIND OF FLUMMOXED BY
8	THIS.
9	IN THOSE INSTANCES, WE WOULD JUST DO THIS
10	REFERRAL, AND I THINK THAT'S SOMETHING THAT THE
11	BOARD CAN GET CONSENSUS ON FAIRLY QUICKLY, AND I
12	THINK WE WOULD HAVE A HIGH COMFORT LEVEL THAT THE
13	SCIENCE WAS THE ISSUE BEING ADDRESSED BY THIS. DOES
14	THAT KIND OF MAKE SENSE?
15	ARE THERE OTHER COMMENTS, THOUGHTS?
16	DR. SLADEK: THIS IS JOHN SLADEK. ON
17	BEHALF OF THE GRANTS WORKING GROUP THEN, IS THERE
18	ANY PROVISION, IF WE TAKE THE SECOND BRANCH FROM
19	JAMES HARRISON'S BIFURCATION, WHERE WE APPOINT
20	ADDITIONAL MEMBERS OF THE GRANTS WORKING GROUP TO
21	REVIEW MATTERS, IS THERE ANY CONSIDERATION THEN
22	ARE WE RECONSIDERING THE GRANT OR ONLY THE ISSUES
23	FOR WHICH THERE ARE QUESTIONS BEING RAISED?
24	CHAIRMAN SHEEHY: ONLY THE ISSUES FOR
25	WHICH THE QUESTION IS BEING RAISED.

1	DR. SLADEK: OKAY. THAT'S FAIRLY
2	STRAIGHTFORWARD TO DO THEN. I THINK WE WOULD BE
3	HAPPY TO HELP AND TAKE WHATEVER PRESSURE WE CAN OFF
4	THE BOARD WHO HAS SO MANY ISSUES TO DEAL WITH.
5	CHAIRMAN SHEEHY: JUST TO BE CLEAR, THERE
6	IS THE OPTION IN HERE I DON'T KNOW IF JAMES
7	MENTIONED IT TO BRING IN OUTSIDE SPECIALISTS IF
8	THERE'S A PARTICULARLY FINE POINT OF SCIENCE THAT
9	MAY NOT BE REPRESENTED ON THE WORKING GROUP. WHAT
10	WE WANT TO DO IS GET IT RIGHT.
11	DR. SLADEK: THANKS.
12	DR. FONTANA: I JUST WANT TO KIND OF
13	CLARIFY. I'VE READ THROUGH SEVERAL OF YOUR
14	PROPOSALS AND WANT TO SUMMARIZE, AND CORRECT ME IF
15	I'M WRONG. NOW WHAT YOU ARE GOING TO DO IN THE
16	WORKING GROUP IS YOU'RE GOING TO SET PRIORITY BOTH
17	ON SCIENTIFIC MERIT AND THEN ON PROGRAMMATIC
18	DISTRIBUTION IN THE DISEASE TEAMS AND FEASIBILITY
19	STUDIES; IS THAT CORRECT?
20	CHAIRMAN SHEEHY: THAT'S THE NEXT ITEM ON
21	THE AGENDA.
22	DR. FONTANA: AFTER DOING THAT, SO YOU
23	WILL TAKE AWAY SOME OF THE BURDEN WHEN IT'S
24	PRESENTED TO THE BOARD WHEN THESE EXTRAORDINARY
25	PETITIONS COME AND THE BOARD CHANGES ITS POSITION
	20
	<b>∠∨</b>

1	BASED ON PROGRAMMATIC REVIEW.
2	CHAIRMAN SHEEHY: I MEAN YOU'RE
3	PRESUPPOSING ADOPTION OF THE PROGRAMMATIC SCORE.
4	DR. FONTANA: WHICH I THINK IS A GOOD
5	IDEA. THEN IF THERE'S FURTHER QUESTION BY THE
6	GRANTEE FROM SCIENTIFIC MERIT, LIKE THE WORKING
7	GROUP MADE A MISTAKE OR THEY THOUGHT THEY MADE A
8	MISTAKE, AND THAT GOES TO THE STAFF. AND THE STAFF
9	REVIEWS IT RIGHT NOW, AND THEY EITHER AGREE OR THEY
10	DON'T AGREE WITH THE GRANTEE. AND THAT'S WHEN IT
11	COMES TO THE BOARD.
12	AND YOU'RE SUGGESTING NOW THAT IF WE CAN'T
13	DECIDE AT THE BOARD LEVEL AT THAT MEETING, THAT YOU
14	WILL SEND IT BACK TO THIS
15	CHAIRMAN SHEEHY: ADMINISTRATIVE AND THE
16	ACTING CHAIR OF THAT GRANTS WORKING GROUP SESSION
17	WHERE THEY CAN ACCESS READILY AVAILABLE INFORMATION.
18	AND IF THEY CAN COME TO A CONCLUSION THAT THE
19	SCIENTIFIC ISSUE HAS NO MERIT, THEN THAT'S FAIRLY
20	DISPOSITIVE. IF IT'S MORE COMPLEX AND THERE'S NOT
21	AGREEMENT BETWEEN THE ACTING CHAIR AND THE
22	ADMINISTRATIVE CHAIR, THEN IT GOES INTO THE LARGER
23	SUBGROUP OF THE GRANTS WORKING GROUP FOR A MORE
24	FORMAL EVALUATION OF THE ISSUES AND A
25	DECISION-MAKING PROCESS.

1	CHAIRMAN KLEIN: TO PROVIDE THE FULL LEGAL
2	PROCESS, IN ANY EITHER CASE IT WILL COME BACK TO THE
3	BOARD FOR A FINAL FOR THE REAL FINAL DECISION.
4	CHAIRMAN SHEEHY: RIGHT.
5	DR. FONTANA: I UNDERSTAND THAT. WHERE I
6	FIND MYSELF PERSONALLY UNCOMFORTABLE IS WHEN I'M
7	PRESENTED AT A BOARD MEETING WITH THIS EXTRAORDINARY
8	PETITION AND I'M SUPPOSED TO MAKE A VOTE BASED UPON
9	SCIENTIFIC REVIEW OR THE OPINION OF THE STAFF
10	WITHOUT HAVING THE GRANT IN FRONT OF ME AND THEN
11	QUESTIONING THE WORKING GROUP'S SCORING OF IT, I
12	FIND IT VERY UNCOMFORTABLE. SO I'M CURIOUS HOW
13	THAT I THINK SEVERAL BOARD MEMBERS FEEL THE SAME.
14	HOW ARE YOU ADDRESSING THAT?
15	CHAIRMAN SHEEHY: WELL, I THINK THE BOARD
16	IS ULTIMATELY THE DECISION MAKER, DR. FONTANA. AND
17	THE OTHER ISSUE HERE IS THAT, AND I WANT TO THANK
18	THE CHAIR FOR GETTING THE DISTRIBUTION OF THE
19	SCORES, THE STANDARD DEVIATION. WHEN YOU HAVE HIGH
20	STANDARD DEVIATION ON AN APPLICATION, YOU MAY END UP
21	WITH A 65, BUT THE LOW END MAY BE 40 AND THE HIGH
22	END MAY BE 85. SO THERE MAY ACTUALLY BE A REAL
23	ISSUE OF SCIENCE THAT'S NOT RESOLVED BY THE WORKING
24	GROUP. YOU HAD TWO DIFFERENT OPTICS ON THAT
25	PARTICULAR ISSUE REPRESENTED AT THE WORKING GROUP,
	22

1	AND YOU REALLY DON'T KNOW PRECISELY. THIS IS
2	MORE THE PEER REVIEW PROCESS IS IN SOME WAYS AN
3	ART FORM.
4	AND SO IF, ESPECIALLY IF THIS IS MISSION
5	CRITICAL SCIENCE, IF THERE'S AN OPPORTUNITY TO TRY
6	GET TO THE BOTTOM OF IT, SOMETIMES PEOPLE COME TO
7	THE BOARD, WE HAD THE ABOODY CASE, THEY'RE ABLE TO
8	PRESENT INFORMATION THAT CLEARLY SHOWS THAT THE
9	APPLICANT DID HAVE WAS GOING DOWN THE RIGHT ROAD.
10	WE'RE ABLE TO RESOLVE THAT AT THE BOARD LEVEL, BUT
11	SOMETIMES WE MAY NOT BE ABLE TO RESOLVE IT AT THE
12	BOARD LEVEL.
13	MR. TORRES: OR WANT TO.
14	CHAIRMAN SHEEHY: OR WANT TO ACTUALLY.
15	THANK YOU, SENATOR TORRES. THIS GIVES US AN
16	OPPORTUNITY NOT TO BE SITTING THERE SUDDENLY
17	CONFRONTED WITH ALL THIS INFORMATION AND HAVING TO
18	MAKE A DECISION.
19	DR. FONTANA: I WOULD JUST LIKE TO SEE THE
20	PROCESS BEFORE IT EVEN CAME TO THE BOARD SO THAT AS
21	BOARD MEMBERS, WE MAKE A COMFORTABLE DECISION.
22	MR. TORRES: JEANNIE, CAN YOU SPEAK UP A
23	BIT? THANK YOU.
24	CHAIRMAN KLEIN: JEANNIE, THIS PROCESS
25	THAT JEFF IS CREATING HERE, I THINK, CAN HELP

1	BECAUSE THE SCIENTIFIC STAFF AND THE REVIEWS WILL
2	ALWAYS TRY AND FILL IN THOSE GAPS AND GIVE US AS
3	MUCH INFORMATION. BUT IF THERE'S A GAP THAT REALLY
4	IS NOT FILLED IN, INSTEAD OF US TRYING TO FIGURE IT
5	OUT, WE CAN SEND IT BACK AND GET AN EXPERT OPINION
6	AND THEN REACH A FINAL DECISION. SO THIS REALLY
7	HELPS ADDRESS THE PROBLEM YOU'RE TALKING ABOUT.
8	CHAIRMAN SHEEHY: I THINK IF YOU LOOK
9	AGAIN HISTORICALLY, WE'RE ONLY PROBABLY TALKING
10	ABOUT (INTERFERENCE WITH THE TRANSMISSION) EVEN FOR
11	DISCUSSION TERMS INTO THIS CATEGORY IN EVERY REVIEW.
12	THAT'S NOT EVEN TO ASSUME THAT AUTOMATICALLY THOSE
13	WOULD BE SENT THROUGH THIS PROCESS.
14	GENERALLY IT'S FAIRLY CLEAR THAT MOST
15	GRANTS ARE FUNDABLE OR NOT FUNDABLE. AND A LOT OF
16	EXTRAORDINARY PETITIONS THAT COME IN, I THINK
17	THEY'RE FAIRLY STRAIGHTFORWARD IN WHETHER OR NOT
18	PEOPLE WERE UNHAPPY WITH THEIR SCORES OR IN WHICH
19	THEY IDENTIFIED A REAL ISSUE THAT WE CAN KIND OF
20	AND STAFF HAS BEEN ABLE TO PROVIDE INFORMATION THAT
21	THERE WAS SOME MERIT TO THEIR DISPUTE OF THE SCORE.
22	DR. FONTANA: OKAY. THANK YOU.
23	MS. SAMUELSON: IT SEEMS TO ME THAT THE
24	TIMES THAT THE EXTRAORDINARY PETITION HAS REALLY
25	BEEN A BENEFIT HAS BEEN WHEN THE PROGRAMMATIC ISSUES

1	ARE KIND OF DEFINED AS SCIENTIFIC MERIT ISSUES AT
2	THE BEGINNING. AND IT TAKES A WHILE, OR BY SOME
3	FOLKS ANYWAY, AND IT TAKES A WHILE FOR US TO TEASE
4	OUT THE FACT THAT THERE'S AN ISSUE THERE AND THAT
5	IT'S DEBATABLE. AND IF THIS IS GOING TO FLESH THAT
6	OUT BETTER, I THINK IT'S A GREAT THING. IF IT'S
7	GOING TO DERAIL THAT HEALTHY SECOND LOOK, THEN I
8	WOULDN'T BE SO CRAZY ABOUT IT.
9	AND SO I'M JUST TRYING TO FIGURE OUT WHICH
10	IT IS BECAUSE I THINK THE DISCOMFORT SOMETIMES IS
11	WHEN THE BOARD FEELS IT'S BEING ASKED TO VOTE
12	AGAINST SCIENTIFIC MERIT, UNDERSTANDABLY. AND I
13	THINK IT'S ONE OF THE KIND OF CENTRAL ISSUES FOR US
14	IN WHAT PRIORITIES DO WE HAVE FOR OUR GRANT
15	PORTFOLIO. AND IT'S KIND OF AND THAT IS KIND OF
16	A WORK IN PROGRESS NOW, I THINK.
17	CHAIRMAN SHEEHY: WELL
18	MS. SAMUELSON: AND AT TIMES I THINK THE
19	EXTRAORDINARY PETITION PROCESS HAS BEEN VERY HELPFUL
20	IN GIVING US A CHANCE TO TALK ABOUT THAT AT THE
21	BOARD LEVEL.
22	CHAIRMAN SHEEHY: WE'RE NOT ELIMINATING
23	THE EXTRAORDINARY PETITION.
24	MS. SAMUELSON: I KNOW. IT'S JUST
25	CHAIRMAN SHEEHY: I THINK THIS IS HIGHLY
	25

1	UNLIKELY TO HAVE AN IMPACT ON 68S AND 69S WHERE THE
2	BOARD PROGRAMMATICALLY OR FOR OTHER REASONS IS
3	WILLING TO MOVE STUFF UP. I THINK THAT THIS WILL
4	HAVE A BIGGER IMPACT ON LOWER SCORES WHERE A REAL
5	SCIENTIFIC ISSUE HAS BEEN IDENTIFIED. IT'S ANOTHER
6	TOOL. AND I DON'T THINK ANYBODY ANY OF US HERE
7	CAN PREDICT HOW THE BOARD WILL UTILIZE THIS TOOL.
8	AND IT MAY BE I UNDERSTAND YOUR FEAR THAT THIS
9	COULD TAKE SOME OF THE ENERGY OUT OF THE BOARD'S
10	CONSIDERATION OF EXTRAORDINARY PETITIONS, BUT THAT'S
11	KIND OF UP TO BOARD MEMBERS NOW ANYWAY AND REALLY IS
12	ALMOST AN INDIVIDUAL QUESTION FOR EACH BOARD MEMBER
13	HOW THEY APPROACH AN EXTRAORDINARY PETITION.
14	CHAIRMAN KLEIN: JOAN, THERE'S NO INTENT
15	TO USE THIS AS A LIMITATION ON THE EXTRAORDINARY
16	PETITION PROCESS. THAT'S A PROCESS THAT'S
17	ESTABLISHED. IT GIVES OPPORTUNITY FOR PUBLIC
18	REVIEW, PUBLIC DEBATE. IT'S A VERY IMPORTANT
19	PROCESS OF RECOURSE.
20	SO THIS IS JUST A TOOL WHERE, YOU KNOW,
21	THE BOARD MIGHT BE FACED WITH SAYING NO BECAUSE THEY
22	CAN'T RESOLVE THIS ISSUE. AND THIS NEEDS TO BE
23	TREATED AS A REAL EXCEPTION; BUT IF THERE'S A REAL
24	SCIENTIFIC ISSUE THAT JUST HAS ESCAPED THE PROCESS
25	AND ARISES LATE AND IT GIVES US AN ABILITY NOT TO

1	EITHER DEFAULT TO A NO OR, ON THE OTHER HAND,
2	DEFAULT TO A YES WHEN WE REALLY DON'T KNOW THE
3	ANSWER.
4	MS. SAMUELSON: YEAH.
5	MR. ROTH: JEFF.
6	DR. FRIEDMAN: IF I COULD OFFER A COUPLE
7	OF THOUGHTS, PLEASE.
8	CHAIRMAN SHEEHY: SURE.
9	DR. FRIEDMAN: ONE IS THAT I THINK IT'S
10	ADMIRABLE TO TRY AND FORMALIZE A PROCESS, WHICH AS
11	VARIOUS OF YOU HAVE SAID, AND I SHARE THE DISCOMFORT
12	WITH THE RIGOR WITH WHICH WE DO THIS, THERE'S A
13	LEGITIMATE DESIRE ON OUR PART AS BOARD MEMBERS NOT
14	TO HAVE MISPERCEPTIONS OR MISTAKES AFFECT IMPORTANT
15	OUTCOMES. THERE'S ALSO A DESIRE ON THE PART OF THE
16	SCIENTISTS TO PRESENT THEIR RESEARCH IN THE BEST
17	POSSIBLE LIGHT AND OF THE PATIENT ADVOCATES AND
18	THOSE AFFECTED BY DISEASES AND CONDITIONS TO MAKE
19	SURE THAT THE PROPER ATTENTION IS PAID TO THEIR
20	PARTICULAR NEEDS. WE'RE TRYING TO BALANCE ALL THESE
21	THINGS AT ONE TIME.
22	I THINK THAT THIS PROPOSAL IS A VERY
23	REASONABLE STEP TO TAKE, BUT I SHARE EVERYBODY'S
24	CONCERN THAT WE DON'T KNOW EXACTLY HOW THIS IS GOING
25	TO TURN OUT. AND RIGHT NOW WE'RE SAYING, OH, I

THINK IT'S ONLY GOING TO BE THIS WAY OR I THINK IT'S
ONLY GOING TO BE THAT WAY.
IF I COULD MAKE A SUGGESTION PLEASE, IT
WOULD BE TO SAY THAT WE TRY THIS FOR A FINITE
PERIOD. IT CAN BE A YEAR, IT CAN BE 18 MONTHS, IT
CAN BE TWO YEARS. I DON'T CARE. BUT THAT WE
FORMALLY TEST IT DURING THAT TIME AND BRING IT BACK
BECAUSE THERE MAY BE UNINTENDED CONSEQUENCES OF WHAT
LOOKS LIKE A VERY REASONABLE THING THIS MORNING
RATHER THAN TRYING TO MAKE THIS THE MOST PERFECT
SYSTEM WHERE WE THOUGHT THROUGH EVERYTHING, WE'RE
STILL GOING TO FORGET THINGS. I THINK WE HAVE TO
TRY AND BRING MORE FORMALITY AND CLARITY TO THIS
PROGRAM.
I REALLY APPRECIATE THE THINKING THAT OS
AND THE STAFF AND OTHER PEOPLE HAVE BROUGHT TO THIS.
AND I'M WILLING TO TEST SOMETHING, AND I WOULD ONLY
ASK THAT WE PLEASE HAVE IT AS A FORMAL TRIAL PERIOD,
BRING IT BACK FOR RECONSIDERATION AT A LATER TIME
SHOULD IT PROVE TOO CUMBERSOME, TOO UNFAIR, TOO
TIME-CONSUMING, WHATEVER. THANK YOU.
CHAIRMAN SHEEHY: I THINK THAT'S A GREAT
IDEA. IN FACT, IF YOU WOULD LIKE TO SUGGEST A TIME
FRAME, I WOULD BE COMFORTABLE WITH WHATEVER. I
ALWAYS THINK IT'S IMPORTANT TO DO ANALYSIS OF THE
28

1	THINGS WE DO.
2	DR. FRIEDMAN: JEFF, THANK YOU. I DON'T
3	KNOW WHAT THE RIGHT TIME IS. I THINK A YEAR MAY BE
4	TOO SHORT BECAUSE WE DON'T HAVE THAT MANY CYCLES
5	THAT GO THROUGH. I THINK TWO YEARS IS PROBABLY AS
6	LONG AS I WOULD LIKE TO TRY IT. BUT HONESTLY, I
7	DON'T CARE; AND IF OTHER PEOPLE ON THE BOARD HAVE
8	STRONG OPINIONS, I PROBABLY AM GOING TO VOTE WITH
9	YOU GUYS. THOSE ARE JUST MY THOUGHTS. THANK YOU.
10	CHAIRMAN SHEEHY: OKAY. WHEN IT COMES
11	TIME TO MAKE AN AMENDMENT, WE'LL STIPULATE WHEN
12	IT COMES TIME TO MAKE A MOTION, WE'LL STIMULATE A
13	TIME PERIOD BY THE MAKER OF THE MOTION. AS I SAID,
14	I'M COMFORTABLE WITH ANY TIME PERIOD.
15	ARE THERE OTHER COMMENTS BEFORE WE GO TO A
16	MOTION? WOULD SOMEONE LIKE TO MAKE A MOTION?
17	CHAIRMAN KLEIN: I WILL MAKE A MOTION FOR
18	APPROVAL. THIS IS BOB KLEIN.
19	CHAIRMAN SHEEHY: WITH THE TIME FRAME.
20	CHAIRMAN KLEIN: WITH THE TIME PERIOD OF,
21	I THINK, 18 MONTHS WILL GO THROUGH A FULL CYCLE OF
22	DIFFERENT KINDS OF GRANTS, AND WE'LL HAVE
23	EXPERIENCE. AND OBVIOUSLY IF WE ARE EXPERIENCING ON
24	AN EARLIER BASIS ISSUES, WE CAN AMEND IT.
25	DR. FRIEDMAN: I'M HAPPY TO SECOND THAT,
	29

1	BOB.
2	CHAIRMAN SHEEHY: OKAY. IS THERE FURTHER
3	DISCUSSION? PUBLIC COMMENT? AND IF ANYONE AT ANY
4	OF THE SITES HAS PUBLIC THERE THAT WANTS TO COMMENT,
5	PLEASE LET ME KNOW. GO AHEAD. WE HAVE PUBLIC HERE
6	IN SAN FRANCISCO TO COMMENT. BUT AFTER THE END OF
7	THE SAN FRANCISCO PUBLIC COMMENT, PLEASE LET ME KNOW
8	IF YOU HAVE A PUBLIC COMMENT AT YOUR SITE.
9	MS. SAMUELSON: THIS IS JOAN. I HAVE A
10	QUESTION. I THINK I HEARD THAT THERE'S SORRY.
11	I'VE FORGOTTEN THE NAME OF IT. NEVER MIND.
12	CHAIRMAN SHEEHY: OKAY.
13	MS. SAMUELSON: I KNOW. SORRY. CAN I
14	HAVE THE FLOOR AGAIN? IT'S JOAN. THERE WAS ONE
15	PIECE OF THIS, I GUESS, THAT COULD BE HANDLED IN THE
16	CONSENT CALENDAR; IS THAT RIGHT? I'M RELUCTANT TO
17	DO THAT.
18	CHAIRMAN SHEEHY: YEAH. THE CHAIR
19	CHAIRMAN KLEIN: IF THE ADMINISTRATIVE
20	CHAIR AND THE ACTING CHAIR SEND BACK A COMMUNICATION
21	THAT THEY DON'T RECOMMEND ANY FURTHER ACTION AND
22	THEY BOTH AGREE, THEN IT CAN GO ON THE CONSENT
23	CALENDAR. BUT ANY BOARD MEMBER CAN PULL IT OFF THE
24	CONSENT CALENDAR, JOAN. SO IT PROVIDES BOTH AN
25	EFFICIENT WAY TO HANDLE IT, BUT IT ALLOWS THE BOARD

1	OVERSIGHT. EVERY ONE OF THE 29 MEMBERS HAS THE
2	RIGHT TO PULL IT OFF THE CONSENT CALENDAR, AND WE
3	HAVE THE RIGHT TO DISCUSS IT.
4	MS. SAMUELSON: AS AN ADDITIONAL
5	PROTECTION, IT MIGHT BE GOOD TO I DON'T KNOW.
6	MAYBE THIS IS LOADING UP WITH TOO MANY PROCEDURES.
7	I KNOW I GO TO THE MEETINGS AND OFTEN THERE ARE
8	SEVERAL ITEMS THAT I'M NOT PREPARED TO THINK ABOUT.
9	I HAVEN'T REALIZED WERE ON THE AGENDA OR WE
10	AGENDIZED THEM VERY LATE IN THE GAME. SO THAT MAY
11	BE WE MAY NOT BE ABLE TO MAKE USE OF THAT
12	CHAIRMAN KLEIN: OKAY.
13	MS. SAMUELSON: READILY ENOUGH TO MAKE
14	A DIFFERENCE. DO YOU KNOW WHAT I'M SAYING? IF WE
15	DON'T KNOW WE NEED TO OBJECT BECAUSE
16	CHAIRMAN KLEIN: SO A PRACTICE AT THE
17	BOARD, CERTAINLY WHILE WE'RE IN THIS PILOT PROGRAM,
18	JOAN, WHAT I WOULD DO AS THE CHAIR IS ADOPT THE
19	PRACTICE THAT JAMES CAN INSTITUTIONALIZE AND THE
20	ATTORNEYS CAN MAKE A RECORD OF THAT JUST WHEN WE
21	SEND OUT THE AGENDA, WE WILL NOTIFY THE BOARD AND
22	THE PUBLIC IF THERE IS A CONSENT ITEM THAT DEALS
23	WITH THIS PRACTICE.
24	MS. SAMUELSON: GREAT.
25	MR. ROTH: JEFF, CAN WE CALL THE QUESTION?
	21

1	CHAIRMAN SHEEHY: WELL, WE HAVE PUBLIC
2	COMMENT HERE. THAT'S THE LAST STEP.
3	MR. REED: THIS IS DON REED. JAMES
4	HARRISON USED THE WORD "MINORITY REPORT". AND I
5	REMEMBER AT A PREVIOUS MEETING OF THIS COMMITTEE,
6	THERE WAS DISCUSSION OR MAYBE AT THE ICOC MEETING,
7	DISCUSSION OF THE MINORITY REPORT, AND SOMEBODY SAID
8	IT WAS AUTOMATIC. ACTUALLY THERE WOULD BE A
9	MINORITY REPORT. BUT I WONDER IF THERE SHOULDN'T BE
10	SOMETHING IN THE FRAMEWORK WHICH SAYS EVERY
11	QUESTION HAS TWO SIDES, BUT THERE WOULD BE AN
12	AUTOMATIC INCLUSION OF A MINORITY REPORT AT THE
13	PRESENCE OR ABSENCE OF EVIDENCE IN THERE THAT COULD
14	HELP TO ELIMINATE REQUESTS THAT WERE NOT REASONABLE.
15	JUST I LIKE TO HEAR BOTH SIDES. I LIKE THE IDEA
16	THERE WOULD BE A ROUTINE INCLUSION OF A MINORITY
17	REPORT AND ANY RATIONALITY THAT LED TO THAT.
18	CHAIRMAN SHEEHY: MINORITY REPORT IS A
19	TERM OF ART HERE, AND IT REPRESENTS WHEN THERE'S A
20	DISPUTE AT THE GRANTS WORKING GROUP AND THE FINDING
21	OF 35 PERCENT OF THOSE WHO WERE TAKING PART IN THE
22	DECISION DON'T AGREE WITH THE MAJORITY. AND SO A
23	MINORITY REPORT WOULD BE FILED IN THOSE
24	CIRCUMSTANCES.
25	AND THAT PROCESS, AS AT THE GRANTS WORKING
	32

1	GROUP, IS INCLUDED HERE. SO THAT WHEN WE GO TO THE
2	LARGER, SMALLER GROUP, THERE IS 35 PERCENT OF THOSE
3	PEOPLE WHO TAKE PART IN THAT DECISION DON'T AGREE
4	WITH THE ENTIRE GROUP'S DECISION, THAT GETS
5	FORWARDED TO THE BOARD. SO THAT'S THE CONTEXT IN
6	WHICH A MINORITY REPORT IS BEING USED HERE. BUT
7	ALWAYS THERE'S BACK AND FORTH, THERE'S EXTRAORDINARY
8	PETITIONS, THERE'S PEOPLE TAKING PRO AND CON,
9	THERE'S A MATTER IN DISPUTE. WE'LL BE HEARING
10	EVIDENCE FROM BOTH SIDES. THAT'S WHAT STIMULATES IT
11	IS THAT THERE'S A LOT OF EVIDENCE FROM BOTH SIDES TO
12	HAVING THIS DEBATE.
13	SO I THINK WE'RE READY TO CALL THE
14	QUESTION UNLESS SOMEONE HAS PUBLIC COMMENT AT
15	ANOTHER SITE. CAN WE HAVE A RESTATEMENT OF THE
16	MOTION, PERHAPS JAMES.
17	MR. HARRISON: YES. THE MOTION IS TO
18	RECOMMEND APPROVAL OF THE ADDITIONAL ANALYSIS
19	OPTION, WHICH IS IDENTIFIED AS OPTION B, FOR A TRIAL
20	PERIOD OF 18 MONTHS. AND UPON EXPIRATION OF THIS
21	PERIOD OF TIME, THE POLICY WILL BE SUBJECT TO
22	RECONSIDERATION BY THE BOARD.
23	CHAIRMAN SHEEHY: OKAY.
24	MS. KING: JACOB LEVIN.
25	DR. LEVIN: YES.

.	Manufacture Manager File Manage
1	MS. KING: MARCY FEIT, HAVE YOU BEEN ABLE
2	TO JOIN US YET? I KNOW YOU'RE PLANNING ON IT. NOT
3	YET.
4	MICHAEL FRIEDMAN.
5	DR. FRIEDMAN: YES.
6	MS. KING: BOB KLEIN.
7	CHAIRMAN KLEIN: YES.
8	MS. KING: JEANNIE FONTANA.
9	DR. FONTANA: YES.
10	MS. KING: DUANE ROTH.
11	MR. ROTH: YES.
12	MS. KING: JOAN SAMUELSON.
13	MS. SAMUELSON: YES.
14	MS. KING: JEFF SHEEHY.
15	CHAIRMAN SHEEHY: YES.
16	MS. KING: OSWALD STEWARD.
17	DR. STEWARD: YES.
18	MS. KING: ART TORRES.
19	MR. TORRES: AYE.
20	MS. KING: AND FOR THE RECORD, THAT MOTION
21	CARRIES.
22	CHAIRMAN SHEEHY: OKAY. BEFORE WE LEAVE
23	THIS ITEM, I MEAN, OS, YOU WANT TO DISCUSS OPTION A
24	OR ARE YOU COMFORTABLE WITH WHERE WE ARE RIGHT NOW?
25	DR. STEWARD: I'M FINE WITH WHERE WE ARE
	34
	24

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	RIGHT NOW.
2	CHAIRMAN SHEEHY: OKAY. THEN PERHAPS
3	WOULD YOU MIND INTRODUCING, DR. STEWARD, THE NEXT
4	ITEM BECAUSE I THINK THAT CAME FROM YOU,
5	PROGRAMMATIC SCORING, ITEM 4.
6	DR. STEWARD: SURE. SO THIS CAME UP
7	REALLY, I THINK, IN RESPONSE TO SEVERAL COMMENTS
8	THAT HAVE BEEN MADE OVER MAYBE THE LAST SIX OR EIGHT
9	MONTHS ABOUT MAYBE SOME OF THE REVIEWERS NOT FULLY
10	UNDERSTANDING THE IMPORTANCE OF THE PROGRAMMATIC
11	PART OF THE REVIEW PROCESS AND GIVING IT SHORT
12	SHRIFT BECAUSE IT SORT OF CAME AT THE END AND
13	PERHAPS THERE WERE PLANES TO CATCH AND SO FORTH.
14	AND I HAVE TO SAY I THOUGHT OF THIS, I
15	THINK, AT THE LAST SCIENTIFIC MEETING AND REALLY WAS
16	THINKING OUT LOUD AT THE TIME. BUT THE IDEA WAS
16 17	THINKING OUT LOUD AT THE TIME. BUT THE IDEA WAS SIMPLY TO MAKE THE PROCESS FORMAL IN THE SAME WAY
17	SIMPLY TO MAKE THE PROCESS FORMAL IN THE SAME WAY
17 18	SIMPLY TO MAKE THE PROCESS FORMAL IN THE SAME WAY THAT THE SCIENTIFIC REVIEW WAS DISCUSSED BY MEMBERS
17 18 19	SIMPLY TO MAKE THE PROCESS FORMAL IN THE SAME WAY THAT THE SCIENTIFIC REVIEW WAS DISCUSSED BY MEMBERS OF THE SCIENTIFIC REVIEW GROUP WITH THE PATIENT
17 18 19 20	SIMPLY TO MAKE THE PROCESS FORMAL IN THE SAME WAY THAT THE SCIENTIFIC REVIEW WAS DISCUSSED BY MEMBERS OF THE SCIENTIFIC REVIEW GROUP WITH THE PATIENT ADVOCATES PRESENT AND LISTENING. THE PROGRAMMATIC
17 18 19 20 21	SIMPLY TO MAKE THE PROCESS FORMAL IN THE SAME WAY THAT THE SCIENTIFIC REVIEW WAS DISCUSSED BY MEMBERS OF THE SCIENTIFIC REVIEW GROUP WITH THE PATIENT ADVOCATES PRESENT AND LISTENING. THE PROGRAMMATIC REVIEW WOULD BE DONE THE SAME WAY AND ACTUALLY
17 18 19 20 21	SIMPLY TO MAKE THE PROCESS FORMAL IN THE SAME WAY THAT THE SCIENTIFIC REVIEW WAS DISCUSSED BY MEMBERS OF THE SCIENTIFIC REVIEW GROUP WITH THE PATIENT ADVOCATES PRESENT AND LISTENING. THE PROGRAMMATIC REVIEW WOULD BE DONE THE SAME WAY AND ACTUALLY SCORED, WHICH WOULD BE THE WAY THAT IT WOULD CLEARLY
17 18 19 20 21 22	SIMPLY TO MAKE THE PROCESS FORMAL IN THE SAME WAY THAT THE SCIENTIFIC REVIEW WAS DISCUSSED BY MEMBERS OF THE SCIENTIFIC REVIEW GROUP WITH THE PATIENT ADVOCATES PRESENT AND LISTENING. THE PROGRAMMATIC REVIEW WOULD BE DONE THE SAME WAY AND ACTUALLY SCORED, WHICH WOULD BE THE WAY THAT IT WOULD CLEARLY INDICATE THAT THE PROCESS WAS TRULY IMPORTANT.

1	AND DISCUSSIONS OF MOVING THINGS UP ON THE BASIS OF
2	PROGRAMMATIC REVIEW WITH A CLEAR UNDERSTANDING OF
3	WHERE THE DIFFERENT GRANTS ACTUALLY FELL WITH
4	RESPECT TO THE ISSUE OF PROGRAMMATIC REVIEW, PROGRAM
5	RELEVANCE, AND SO FORTH. AND THEN THE IDEA THAT
6	BOTH OF THOSE SCORES WOULD END UP BEING REPORTED TO
7	THE BOARD IN ADDITION TO THE ORDER EVENTUALLY
8	REACHED BY THE COMBINED REVIEW GROUP. SO THAT WAS
9	THE IDEA.
10	CHAIRMAN SHEEHY: OKAY. DO FOLKS WANT TO
11	DISCUSS THIS?
12	CHAIRMAN KLEIN: SO CAN I ASK A QUESTION
13	OF OS?
14	CHAIRMAN SHEEHY: SURE. BE MY GUEST.
15	CHAIRMAN KLEIN: SO, OS, EACH OF THE RFA'S
16	IS DIFFERENT. SO THERE'S DIFFERENT PROGRAMMATIC
17	ISSUES THAT WOULD ARISE IN EACH RFA. SO IT WOULD
18	SEEM TO ME TO BE DIFFICULT TO ARRIVE AT THE SAME
19	CRITERIA FOR SCORING BECAUSE OF THE GREAT
20	DIFFERENCES. SO, FOR EXAMPLE, IN THE TRAINING
21	PROGRAM OR IN THE BRIDGES PROGRAM, YOU KNOW,
22	EXPANDING ACCESS TO THE EVERYONE IN THE STATE HAVING
23	DIVERSITY MIGHT BE A CRITERIA, BUT THAT'S A NOT A
24	CRITERIA IN EARLY TRANSLATION. SO WE'D HAVE TO FIND
25	SOME WAY TO CREATE A WHOLE SET OF CRITERIA FOR EACH

1	RFA.
2	AND IN LISTENING TO 30 DIFFERENT PEER
3	REVIEWS OVER THE LAST SIX YEARS, I'M ALWAYS
4	MARVELLING AT THE INSIGHTS THAT THE DIFFERENT PEOPLE
5	BRING UP DURING PROGRAMMATIC REVIEW, RAISING ISSUES
6	THAT I HADN'T THOUGHT ABOUT AS BEING IMPORTANT. IF
7	THOSE WEREN'T PART OF THE, IN QUOTE, FORMAL
8	CRITERIA, THE ISSUE IS HOW DO YOU INCORPORATE THEM
9	INTO THE SCORING PROCESS? SO I'M TRYING TO
10	UNDERSTAND MECHANICALLY HOW WE WOULD CARRY THIS OFF.
11	DR. STEWARD: RIGHT. ACTUALLY IT'S A VERY
12	INTERESTING QUESTION, BOB. I HADN'T REALLY THOUGHT
13	ABOUT HAVING A SET OF PREDEFINED CRITERIA FOR
14	PROGRAMMATIC REVIEW. I THINK YOU MAKE A VERY
15	EXCELLENT POINT, THAT THE THINGS THAT BECOME
16	RELEVANT FOR PROGRAMMATIC REVIEW, EVERYONE SORT OF
17	HAS SOMETHING IN THEIR HEART OF HEARTS THAT
18	REPRESENTS AN ELEMENT IN PROGRAMMATIC REVIEW. AS
19	YOU SAID, PUTTING THOSE DOWN ON PAPER IS NOT ALWAYS
20	EASY AND CERTAINLY NOT ALWAYS EASY TO PUT THEM DOWN
21	IN ADVANCE. I THINK, IN FACT, THAT DIFFERENT
22	ASPECTS OF PROGRAMMATIC REVIEW MIGHT CARRY HUGELY
23	DIFFERENT WEIGHT DEPENDING ON THE CONTEXT.
24	SO I'M NOT SURE THAT YOU REALLY WANT TO DO
25	ANYTHING THAT FORMAL IN TERMS OF CRITERIA IN

1	ADVANCE. EVEN WITHOUT CRITERIA, THE PATIENT
2	ADVOCATES WHO WERE THERE FORM VERY FIRM OPINIONS
3	ABOUT THE PROGRAMMATIC RELEVANCE OF A PARTICULAR
4	PROJECT AS IT'S BEING DISCUSSED AND AT THE END OF
5	THE DAY HAVE VERY FIRM OPINIONS ABOUT THE
6	RELATIONSHIP BETWEEN DIFFERENT PROJECTS. AND I'M
7	NOT SURE THAT IT'S NECESSARY TO OBJECTIFY THAT IN
8	ADVANCE.
9	DR. OLSON: I JUST WANTED TO MAKE A
10	COMMENT WHICH PERHAPS ADDRESSES YOUR ASSUMPTION OF
11	THE NEED FOR ADDITIONAL MODIFICATION. I WOULD
12	COMMENT, AND PERHAPS MR. SHEEHY, SENATOR TORRES, AND
13	MR. KLEIN CAN CORROBORATE THIS, BUT CERTAINLY AT
14	MANY OF THE ALMOST ALL OF THE GRANTS WORKING
15	GROUP MEETINGS OVER THE PAST YEAR, I BELIEVE THERE
16	HAS BEEN THE SCIENTIFIC MEMBERS OF THE TEAM HAVE
17	PARTICIPATED FULLY IN THE PROGRAMMATIC REVIEW, AND
18	THEY DO CONSIDER A PART OF IT. THEY DO NOT RUN OFF
19	TO DO THE THING.
20	I WOULD ALSO REMIND I MEAN I DON'T
21	THINK I NEED TO REMIND THE BOARD, BUT OBVIOUSLY NOT
22	JUST AT THE GRANTS WORKING GROUP, BUT THAT IS
23	SOMETHING THE BOARD IT FALLS WITH THE PURVIEW OF
24	THE BOARD AS WELL, THE PROGRAMMATIC CONSIDERATIONS.
25	SO THERE ARE ACTUALLY SEVERAL OPPORTUNITIES AT WHICH

1	THESE CONSIDERATIONS CAN BE BROUGHT TO BEAR AND
2	DISCUSSED.
3	DR. FRIEDMAN: I THINK THAT THE CHALLENGE
4	OF FORMALIZING THE PROGRAMMATIC DESIRES IS REAL, BUT
5	I'D LIKE TO ARGUE TO PLEASE TRY AND DO IT BECAUSE
6	THERE ARE A LOT OF VALUABLE AND WORTHWHILE GOALS
7	THAT COMPETE WITH ONE ANOTHER. AND I THINK IT WOULD
8	BE BETTER FOR US TO STATE THOSE FORMAL EXPECTATIONS
9	SO WE'LL KNOW HOW TO SCORE THESE THINGS. THE
10	DYNAMICS THAT WE'VE ALL DEALT WITH, AND I THINK
11	REASONABLY SUCCESSFULLY, A DESIRE TO HAVE BROAD
12	INFRASTRUCTURE BUILT THROUGHOUT THE ENTIRE STATE, A
13	REAL SENSITIVITY TO THE NEEDS OF SO MANY DIFFERENT
14	PATIENT POPULATIONS, BEST SCIENTIFIC OPPORTUNITIES,
15	EXTRAORDINARY ONE-TIME CONVERGENCE OF FACTORS THAT
16	WE TRY AND TAKE ADVANTAGE OF, THOSE ARE ALL THINGS
17	THAT ARE DIFFICULT TO STATE BECAUSE ONE WILL COMPETE
18	DIRECTLY WITH ANOTHER.
19	BUT I WOULD STRONGLY URGE US, PLEASE, IF
20	WE'RE GOING TO USE IF WE'RE GOING TO HAVE
21	PROGRAMMATIC PRIORITIES, AND I THINK IT'S GOOD THAT
22	WE DO AND IT'S RIGHT THAT WE DO, THAT WE SET WHAT
23	THOSE ARE DOWN.
24	AND I MUST SAY I AGREE WITH BOB'S POINT
25	THAT THEY MIGHT BE SLIGHTLY DIFFERENT, THEY MIGHT BE

1	VERY DIFFERENT FROM ONE RFA TO ANOTHER, BUT I THINK
2	IT'S REALLY WORTHWHILE TO PUT THEM IN. OTHERWISE
3	I'M AFRAID WE LET EMOTIONS AND OTHER THINGS DICTATE
4	DECISIONS. AND THAT'S OKAY. WE'RE NOT DOING THIS
5	DISPASSIONATELY. WE'RE DOING IT WITH COMPASSION AND
6	CARE, BUT WE'VE GOT I THINK WE HAVE TO TRY AND
7	MAKE IT AS OBJECTIVE AND CLEAR AS WE CAN. THANK
8	YOU.
9	CHAIRMAN SHEEHY: DR. OLSON HAD ANOTHER
LO	COMMENT.
L1	DR. OLSON: I JUST WANTED TO MAKE THE
L2	COMMENT THAT ACTUALLY IN EACH RFA WE DO AT LEAST PUT
L3	IN POTENTIAL POSSIBLE PROGRAMMATIC CONSIDERATIONS
L4	THAT TEND TO DO WITH MEETING THE OBJECTIVES OF THE
L5	RFA. SO IF I JUST MIGHT GIVE THE BOARD AN EXAMPLE.
L6	FOR THE IMMUNOLOGY PROGRAM, IT WAS THE APPROPRIATE
L7	BALANCE AMONG APPLICATIONS ADDRESSING THE FOCUS
L8	AREAS OF STEM CELL TRANSPLANTATION IMMUNOLOGY
L9	RESEARCH, THOSE FOCUS AREAS WERE PRESENTED TO THE
20	BOARD AS PART OF THE CONCEPT PLAN. SO PROGRAMMATIC
21	CONSIDERATION COULD BE THAT BALANCE.
22	WE ALWAYS INCLUDE OTHER CONSIDERATIONS
23	FROM THE PERSPECTIVE OF THE PATIENT ADVOCATES. THE
24	APPROPRIATE BALANCE BETWEEN INNOVATION, RISK, AND
25	FEASIBILITY. AND I THINK, AS I SAY, I BELIEVE THESE

1	ARE ADEQUATELY ADDRESSED BY THE VICE CHAIR IN THE
2	CONTEXT OF PROGRAMMATIC DISCUSSION AT THE GRANTS
3	WORKING GROUP. SO THAT'S AN EXAMPLE.
4	I'M JUST SAYING THERE ARE COMPARABLE TYPES
5	OF GENERAL PROGRAMMATIC CRITERIA THAT ARE PUT FORTH
6	IN THE APPLICATION USUALLY BASED ON THE OBJECTIVE
7	BASED ON THE OBJECTIVES OF THE RFA THAT ARE APPROVED
8	BY THE BOARD AS PART OF THE CONCEPT PLAN.
9	CHAIRMAN SHEEHY: SO DO WE HAVE ADDITIONAL
10	COMMENT?
11	DR. LEVIN: CAN I CLARIFY PAT'S COMMENT?
12	SO YOU'RE SAYING YOU FEEL THAT THE PROGRAMMATIC
13	REVIEW IS ALREADY WELL BUILT INTO THE SCIENTIFIC
14	REVIEW PROCESS, AND AS SUCH IS REFLECTED IN WHATEVER
15	THE SCORE THAT COMES OUT OF THE GRANTS WORKING GROUP
16	IS?
17	CHAIRMAN SHEEHY: I THINK HER POINT WOULD
18	BE THAT IT'S REFLECTED IN THE RECOMMENDATIONS THAT
19	COME FROM THE GRANTS WORKING GROUP.
20	CHAIRMAN KLEIN: IT OCCURS AFTER THE
21	SCORING.
22	CHAIRMAN SHEEHY: SO IT'S REFLECTED IN THE
23	RANK ORDER OF THE APPLICATIONS THAT COME TO THE
24	BOARD WHERE THERE IS SOME MOVEMENT IN VIRTUALLY
25	AT THE END OF EVERY REVIEW.
	И1

1	DR. LEVIN: AS I UNDERSTOOD IT, THE POINT
2	OF THIS AGENDA ITEM WAS TO CLARIFY THAT FOR THE
3	BOARD WHEN THAT HAPPENED AND TO BASICALLY GIVE IT A
4	NUMERICAL SCORE OR TO GIVE IT A LITTLE BIT MORE
5	GIVE US AN UNDERSTANDING OF WHY AND WHEN THAT
6	HAPPENED BECAUSE THE BOARD SOMETIMES MOVES THINGS UP
7	AND DOWN PROGRAMMATICALLY ALMOST IN THE DARK.
8	DR. STEWARD: JUST TO AMPLIFY, I THINK ALL
9	OF THAT IS TRUE. AND IT ACTUALLY IN A SENSE JUST
10	MAKES THE PROCESS KIND OF A FORMAL STEP. BUT REALLY
11	THERE IS THE ADDITIONAL RATIONALE, JUSTIFICATION,
12	WHATEVER THAT IT DOES REALLY EMPHASIZE THAT THE
13	PROGRAMMATIC PART OF THE REVIEW PROCESS AT THE LEVEL
14	OF THE SCIENTIFIC WORKING GROUP IS EVERY BIT AS
15	IMPORTANT AS THE SCIENTIFIC SCORING. AND THAT IT
16	REALLY IS A PROCESS THAT CAN BE QUANTIFIED AND IS
17	FORWARDED TO THE BOARD, NOT JUST IN TERMS OF THE
18	FINAL SCORE AND FINAL POSITION, BUT ALSO MAYBE IN
19	TERMS OF THE HETEROGENEITY OF SCORES. I THINK THAT
20	THAT'S ONE OF THE LESSONS THAT WE'VE LEARNED, THAT
21	KNOWING THAT HETEROGENEITY IS ACTUALLY VERY USEFUL.
22	JEFF, YOU HAVEN'T REALLY SAID VERY MUCH.
23	I'D BE CURIOUS WHAT YOUR COMMENTS WERE AS FAR AS
24	THAT ASPECT OF IT.
25	CHAIRMAN SHEEHY: HONESTLY, I DON'T MY
	42
	· —

1	DIFFICULTY IS THE OBJECTIVITY ASPECT OF THIS. I'VE
2	ALWAYS SAID, HAVING CHAIRED THE PROGRAMMATIC REVIEW,
3	AND I'VE HAD DISCUSSIONS WITH STAFF AND DURING THE
4	REVIEW WITH OTHER PATIENT ADVOCATES, WHAT ARE GOING
5	TO BE THE PROGRAMMATIC CONSIDERATIONS. AND THAT IS
6	AN INTUITIVE MORE THAN AN OBJECTIVE PROCESS AND
7	REFLECTS, I THINK, KIND OF THE NATURE OF
8	PROGRAMMATIC REVIEW.
9	PEOPLE SIT IN A REVIEW, THEY HEAR ISSUES,
10	THEY COME UP, SOMETIMES IT'S VERY STRAIGHTFORWARD.
11	WE'RE NOT REPRESENTED IN THIS DISEASE. SOMETIMES
12	IT'S VERY STRAIGHTFORWARD. WITH TOOLS AND
13	TECHNOLOGY, FOR INSTANCE, WHERE WE WERE TRYING TO
14	HIT FIVE DIFFERENT TYPES OF APPROACHES. BUT IN
15	OTHER INSTANCES IT'S MORE NUANCED. AND I WORRY
16	ABOUT OBJECTIFYING A PROCESS THAT IS MORE ORGANIC
17	AND INTUITIVE AND REFLECTS A SENSE OF EVERYBODY
18	SITTING IN THAT ROOM. SOMETIMES IT GOES ON FOR TWO
19	DAYS BEFORE THEY COME TO PROGRAMMATIC REVIEW. AND
20	THEY GET A FEEL, AND THEY KIND OF LIKE CERTAIN
21	APPROACHES AND CERTAIN SCIENCE, AND THEY, YOU KNOW,
22	SOMETIMES AND THEY DO MAKE EXTRA JUDGMENTS.
23	I JUST THINK ONE OF THE DIFFICULTIES WITH
24	PROGRAMMATIC REVIEW, I THINK PART OF IT'S BEEN IS
25	BEING ADDRESSED WITH DR. SLADEK, AND I'M VERY

1	GRATEFUL FOR HIS PARTICIPATION IN KIND OF SETTING UP
2	WHAT IT'S ABOUT AT THE BEGINNING OF THE MEETING AND
3	BEFORE WE DO PROGRAMMATIC REVIEW, AND I THINK HE'S
4	BEEN VERY HELPFUL. THAT DEFINITELY HELPS. AND WE
5	CAN'T CONTROL FOR THIS AND I DON'T THINK WE SHOULD.
6	IT OFTEN DEPENDS ON THE ACTING CHAIR OF
7	THAT REVIEW SESSION. SOME ACTING CHAIRS WHO HAVE
8	BEEN INVOLVED WITH OUR PROCESS A LOT ARE VERY ACTIVE
9	IN PROGRAMMATIC REVIEW, AND THEY CAN REALLY CHANGE
10	AND INNERVATE THE PROCESS. OTHERS NOT THAT FAMILIAR
11	WITH OUR PROCESS OR MAYBE NOT THAT KEEN ON
12	PROGRAMMATIC REVIEW, THEY OFFER A DIFFERENT TEXTURE.
13	BUT, AGAIN, THOSE CHAIRS WERE CHOSEN
14	BECAUSE OF THEIR EXPERTISE. I DON'T WANT TO SAY
15	CHOOSE A DIFFERENT CHAIR. I THINK SOME OF THIS
16	VARIATION, THIS VARIABILITY IS BENEFICIAL TO US AS
17	AN ENTITY. I THINK TOO MUCH WHEN YOU GO DOWN A
18	REALLY WELL-DRAWN PATH, I THINK YOU TEND TO LOSE
19	SOMETHING. AND REVIEWS ARE GOING TO BE DIFFERENT.
20	A LOT OF YOU PARTICIPATE IN SCIENTIFIC
21	REVIEWS ALL THE TIME, AND I JUST THINK THAT EACH ONE
22	HAS ITS OWN CHARACTER. I DON'T KNOW IF OBJECTIFYING
23	THIS PROCESS WILL HELP TO MAINTAIN AND KEEP A GOOD
24	SPIRIT, OR IT MIGHT BE A LIMITATION ON THE FREE FLOW

OF THE DISCUSSION AND THE KIND OF INTUITIVE, ORGANIC

25

1	WAY IN WHICH THESE RECOMMENDATIONS, WHICH ARE
2	OBJECTIVE. THE RECOMMENDATIONS THAT COME OUT AT THE
3	END ARE OBJECTIVE. THEY'RE RANKED, THEY MOVE STUFF
4	UP AHEAD OF OTHER STUFF. THERE'S USUALLY SOME
5	FAIRLY GOOD CONTEXT FROM THE WORKING GROUP ON WHY
6	THEY MOVED STUFF UP.
7	SO THE BOARD'S GENERALLY BEEN AMENABLE TO
8	STUFF THAT'S BEEN MOVED UP.
9	MR. ROTH: JEFF, IS THERE A REPORT ABOUT
10	THAT?
11	CHAIRMAN SHEEHY: ON HOW IT WORKS?
12	MR. ROTH: NO, JUST WHEN YOU HAVE THAT
13	DISCUSSION AND YOU MOVE THINGS AROUND, DOES ANYBODY
14	TAKE NOTES AND ACTUALLY REPORT ON WHY THINGS WERE
15	DONE?
16	DR. OLSON: WHENEVER THERE IS A
17	PROGRAMMATIC DISCUSSION, THAT IS CAPTURED, THAT
18	DISCUSSION IS CAPTURED AT THE END OF THE SUMMARY.
19	MR. SWEEDLER: AND JUST TO PROVIDE SOME
20	ADDITIONAL DETAIL ABOUT HOW THAT LOOKS, THE MOTION
21	THAT WAS MADE IS ALWAYS DESCRIBED, THE ARGUMENTS
22	THAT WERE GIVEN BACK AND FORTH, AND THE VOTE THAT
23	WAS TAKEN ON THAT MOTION. SO THE OUTPUT, THE VIEWS
24	OF THE RANGE OF MEMBERS OF THE GRANTS WORKING GROUP,
25	THERE'S AN ATTEMPT TO CAPTURE THAT AND EXPRESS THAT

1	IN THE SUMMARY TO THE BOARD.
2	MR. ROTH: THE SUMMARIES ONE BY ONE, BUT I
3	WAS LOOKING MAYBE IT WOULD BE HELPFUL, I DON'T KNOW
4	IF THIS IS WHERE YOU WERE GOING WITH THIS, OS, BUT
5	JUST INSTEAD OF HAVING TO LOOK FOR THOSE ONE BY ONE
6	THROUGH A LOT OF GRANTS, IT MIGHT BE HELPFUL. JEFF,
7	YOU DO A NICE JOB USUALLY OF TALKING ABOUT THAT, BUT
8	IT MIGHT BE INTERESTING TO HAVE SORT OF A REPORT
9	ABOUT WHAT THE PROGRAMMATIC DISCUSSION WAS SO WE
10	HAVE A FLAVOR FOR IT.
11	CHAIRMAN SHEEHY: NO.
12	MR. ROTH: THE CONTEXT OF THE ROOM IS VERY
13	IMPORTANT.
14	CHAIRMAN KLEIN: YOU MEAN A PARAGRAPH OR
15	SOMETHING?
16	MR. ROTH: YES.
17	CHAIRMAN KLEIN: JUST TO CAPTURE, DUANE,
18	YOUR COMMENT IN TRYING TO CAPTURE THE ESSENCE OF IT
19	AND IN FOLLOWING ON JEFF'S COMMENT, ONE OF THE
20	THINGS PROBLEMS WITH THE SCORING SYSTEM, IF YOU
21	HAD FIVE SCORING CATEGORIES FOR EACH RFA AND YOU HAD
22	DISTRIBUTION OF POINTS BETWEEN THEM, IT WOULDN'T
23	CAPTURE, FOR EXAMPLE, THAT IN PROGRAMMATIC IT CAME
24	UP THAT THIS WAS A PIVOTAL IT WAS A HIGH RISK
25	ITEM. IT HAD BEEN SCORED DOWN BECAUSE IT WAS SUCH

HIGH RISK AND HIGH AMBITION. BUT IF THEY COULD MAKE
THIS DISCOVERY BE SO PIVOTAL FOR THIS PARTICULAR
FIELD, SO THAT THE WHOLE PROGRAMMATIC DECISION WAS
SWAYED ON HOW PIVOTAL THAT DISCOVERY WOULD BE AND
HOW IMPORTANT THE IMPORTANCE OF THE WORK ITSELF.
SO, FOR EXAMPLE, TO GET A PARKINSON'S CELL
LINE THAT COULD BE USED BY LARGE NUMBERS OF
RESEARCHERS COULD BE PIVOTAL TO PARKINSON'S RESEARCH
MOVING FORWARD AND HAVING STANDARD
CHARACTERIZATIONS, AND THAT SPECIFIC FACT COULD
COMPENSATE FOR A LOT OF RISK AND LOT OF OTHER
ISSUES. THE QUESTION IS I DO THINK MAYBE
FORMALIZING THE COMMENT, AS DUANE SUGGESTS, AND
CAPTURING THE ESSENCE OF THE DISCUSSION REALLY
PROVIDES THE INSIGHT TO THE DISCUSSION BETTER THAN
HAVING A WHOLE SCORING SYSTEM.
AND THE QUESTION WITH THE SCORING SYSTEM
IS THE, YOU KNOW, THE SCORE IF IT WAS TAKEN DURING
THE SESSION, AND I WILL SAY THE SCIENTISTS HAVE BEEN
GREAT IN BEING AND STAYING AND PARTICIPATING IN THIS
DESCRIPTION FINANCIAL FOR THE PROPERTY OF THE
DISCUSSION FULLY, BUT WHAT I WOULD SAY IS THAT WOULD
YOU TABULATE THE SCORES AT THE VERY END? AND IF YOU
YOU TABULATE THE SCORES AT THE VERY END? AND IF YOU

1	THE ESSENCE OF IT, INSTEAD OF A SCORE, IT GIVES YOU
2	AN INFORMED INSIGHT INTO THE ESSENCE OF THE
3	DISCUSSION.
4	DR. LEVIN: I AGREE. I HAVE TO AGREE WITH
5	BOB AND DUANE ON THIS, THAT WE NEED MORE
6	INFORMATION. I ASSUME THAT'S WHAT THIS ENTIRE
7	PROCESS IS ABOUT TODAY IS TO TRY AND GET MORE
8	INFORMATION TO THE BOARD ABOUT THE SCORING AND THE
9	DECISION-MAKING PROCESS. AND I FIND AT LEAST WITH
10	THE SUMMARIES THAT THERE ISN'T ENOUGH THERE TO
11	REALLY UNDERSTAND WHY THINGS WERE MOVED
12	PROGRAMMATICALLY. IT USUALLY SAYS SOMETHING LIKE A
13	MOTION WAS MADE TO MOVE THIS GRANT UP
14	PROGRAMMATICALLY AND IT FAILED SEVEN TO FIVE, AND
15	THAT'S ABOUT IT. AND IT DOESN'T SAY WHY OR IS IT
16	BECAUSE IT WAS TOO RISKY OR WAS IT BECAUSE THERE WAS
17	SOME SCIENTIFIC PROBLEMS. AND IT WOULD BE REALLY
18	USEFUL TO GET, NOT ONLY MORE INFORMATION ON THAT
19	INDIVIDUAL GRANT, BUT, AS DUANE SUGGESTED,
20	INFORMATION ABOUT THE CONTEXT, THE TEXTURE OF THE
21	DISCUSSION AS A WHOLE THAT WAS SAID IF THERE WAS
22	SOME DISEASES THAT WERE BETTER REPRESENTED OR OTHERS
23	THAT WEREN'T OR SOME PARTICULAR CONFLAGRATION OF
24	GREAT OPPORTUNITIES THAT CAME TOGETHER THAT MADE
25	PEOPLE WANT TO MOVE THINGS UP OR DOWN TO MAKE ROOM

1	FOR OTHERS. IT WOULD BE REALLY USEFUL TO EVEN GET A
2	COUPLE OF PARAGRAPHS ABOUT THAT DISCUSSION IN THE
3	SUMMARY REPORT OR OVERALL FOR THE WHOLE GRANTS
4	WORKING GROUP SESSION FOR THAT RFA.
5	MS. SAMUELSON: I'M WONDERING IF WE MIGHT
6	NOT HAVE THE DISCUSSION AT THE BEGINNING OF THE
7	MEETING BECAUSE IT SHOULD, I THINK, BE INFORMING THE
8	SCIENTIFIC MERIT VOTING AS WELL AS THE PROGRAMMATIC
9	SESSION.
10	CHAIRMAN KLEIN: JOAN, IT IS INTENDED
11	THERE'S TWO THINGS THAT YOU MAY BE ADDRESSING.
12	HAVING A DISCUSSION AT THE BEGINNING OF THE SESSION
13	ON PROGRAMMATIC CONSIDERATIONS, IS THAT WHAT YOU'RE
14	SAYING?
15	MS. SAMUELSON: YEAH. YES.
16	CHAIRMAN KLEIN: WELL, LAYING OUT
17	PROGRAMMATIC CONSIDERATIONS FOR CONSIDERATION DURING
18	THE PROGRAMMATIC PORTION IN A DISCUSSION, MY
19	UNDERSTANDING IS DR. SLADEK IS DOING A VERY GOOD JOB
20	NOW OF ENHANCING THIS PROCESS BY DESCRIBING
21	ELEMENTS, WHO ALL THE PARTICIPANTS ARE AND WHAT
22	THEIR ROLES ARE. AND IT COULD BE ADDED TO THAT
23	PORTION OF IT, BUT THE SCIENTIFIC SCORES ARE REALLY
24	INTENDED TO BE THE SCIENTIFIC SCORES. AND THE
25	PROGRAMMATIC PORTION IS TO CONSIDER THE PROGRAMMATIC

1	CONSIDERATIONS. BUT LETTING THEM KNOW IN GREATER
2	DETAIL AT THE BEGINNING OF EACH SESSION WHAT THE
3	PROGRAMMATIC CONSIDERATIONS ARE THEY'RE GOING TO BE
4	LOOKING AT LATER, REMINDING THEM OF THAT IS
5	SOMETHING GIL TRIES TO DO AND DR. SLADEK COULD
6	SUPPLEMENT IT. JEFF, WHAT DO YOU THINK?
7	MS. SAMUELSON: JUST A SECOND. LET ME ASK
8	SOMETHING ELSE. IF IT'S BALANCING THE PORTFOLIO,
9	MAYBE YOU'RE RIGHT AND MAYBE THAT BELONGS TOWARD THE
10	END. BUT ISSUES OF WHETHER A GIVEN GRANT COULD BE
11	ADVANCING OUR SCIENTIFIC AGENDA AND THE CURES AGENDA
12	FASTER THAN, SAY, SOME OTHER FOCUS IS PART OF THE
13	SCIENTIFIC MERIT OF THE APPLICATION. DON'T YOU
14	THINK?
15	CHAIRMAN SHEEHY: I THINK THAT THAT'S
16	BUILT INTO THE RFA. AND THE PURPOSE OF THE RFA, I
17	THINK, IS DISCUSSED BEFORE WE DO THE SCIENTIFIC
18	SCORING. SO I DON'T KNOW I DON'T KNOW IF THAT
19	WOULD I REALLY
20	MS. SAMUELSON: IT'S DOUBLING UP OR
21	SOMETHING. WELL, I THINK IT IS IN THE RFA, BUT I
22	GUESS I'M PERCEIVING A PROBLEM AND SEEING THIS AS A
23	POSSIBLE SOLUTION. BECAUSE ALL ALONG IT JUST SEEMED
24	TO ME THAT THERE'S KIND OF A CHRONIC PROBLEM THAT
25	THE RISKS OF A GIVEN GRANT ARE ALWAYS DISCUSSED IN

Т	DETAIL, BUT THE REWARDS ARE NOT. AND THAT'S KIND OF
2	PUT OFF. OH, WELL, THAT'S A PROGRAMMATIC ISSUE
3	WHEN, IN FACT, WHAT THAT DOES IS SKEW THE SCORES. I
4	THINK WE'VE SEEN THAT ROUTINELY, THAT MORE
5	TRANSLATIONAL GRANTS DON'T SCORED AS WELL. I THINK
6	THAT'S A BIG PART OF WHY.
7	SO HAVING THIS BE PART OF THE DISCUSSION
8	AND REALLY FOCUSED ON AT THE BEGINNING WILL PUT THAT
9	IN A CONTEXT FOR THE SCIENTIFIC MERIT AS WELL. AND
10	I PERCEIVE ANOTHER PROBLEM WHICH IT COULD HELP SOLVE
11	WHICH IS WE HAVE FEWER AND FEWER SCIENTISTS WHO ARE
12	FAMILIAR WITH OUR PROCESS INSTEAD OF THE WAY I THINK
13	THE SYSTEM WAS ORIGINALLY INTENDED TO WORK WHERE
14	WE'RE ALL WORKING TOGETHER AND GETTING MORE FAMILIAR
15	WITH THE PROCESS. WE'VE HAVING MORE AND MORE
16	SCIENTISTS WHO HAVEN'T BEEN A PART OF THE PROCESS.
17	SO THIS IS UNFAMILIAR TO THEM, AND THERE'S BEEN
18	QUITE A BIT OF CRITICISM OF THE PROGRAMMATIC PROCESS
19	AND THAT IT'S SOMEHOW TAINTING THE SCIENTIFIC MERIT.
20	DR. STEWARD: I JUST WANT TO SAY THAT
21	REALLY IT WAS THIS KIND OF CONCERN THAT REALLY
22	TRIGGERED ME TO START THINKING ABOUT THIS IN THE
23	BEGINNING. THE SCIENTIFIC REVIEW GROUP IS DOING A
24	SPECTACULAR JOB REVIEWING THE SCIENCE. THERE IS A
25	NEED TO BRING IN NEW MEMBERS OF THE SCIENTIFIC

1	REVIEW GROUP TO COVER THE WATERS IN TERMS OF
2	EXPERTISE. BUT THE CONSEQUENCE OF THAT IS AND
3	ESPECIALLY WHEN THERE'S NOT SOME KIND OF THREAD
4	THROUGH IT. SO IF, JOHN, FOR EXAMPLE, WAS ALWAYS
5	THE CHAIR AND COULD LEAD THE DISCUSSION ALWAYS, THAT
6	WOULD SOLVE THE PROBLEM IMMEDIATELY. BUT WHEN
7	THERE'S A DIFFERENT CHAIR AND PERHAPS EVEN A LARGELY
8	DIFFERENT GROUP, THE WHOLE PROCESS OF PROGRAMMATIC
9	REVIEW OR SORT OF PATIENT ADVOCATE'S VIEWPOINT, I
10	THINK SOMETIMES IT MAY NOT BE SEEN IN THE SAME WAY
11	AS IT IS WITH THE CORE COMMITTEE.
12	IN SOME WAY FURTHER SORT OF INSTANTIATING
13	THE PROCESS WOULD HELP TO SOLVE THAT PROBLEM. THAT
14	REALLY WAS THE MOTIVATION FOR MY STARTING TO THINK
15	ABOUT THIS IN THE BEGINNING. I DON'T THINK IT
16	REALLY MAKES TOO MUCH DIFFERENCE WHAT KIND OF
17	PROCESS WE USE, BUT JUST SOMETHING TO REALLY MAKE IT
18	INTO A CLEAR PROCESS.
19	CHAIRMAN SHEEHY: MAYBE IF I COULD KIND OF
20	CUT TO THE CHASE BECAUSE I DON'T THINK WE'RE GOING
21	TO GET TO A DECISION POINT TODAY. SO MAYBE I CAN
22	IDENTIFY THREE POINTS FOR FURTHER STUDY.
23	ONE IS THE POTENTIAL FOR A REPORT BACK
24	FROM THE GRANTS WORKING GROUP ON PROGRAMMATIC
25	REVIEW, AND MAYBE I CAN TALK TO STAFF. I DON'T WANT

1	TO PUT THEM UNDER THE GUN, BUT SEE WHAT MIGHT BE
2	FEASIBLE IN TERMS OF AN ACTUAL REPORT ON THE
3	PROGRAMMATIC REVIEW THAT MAYBE STANDS SEPARATE FROM
4	EACH APPLICATION SO PEOPLE CAN KIND OF GET A TEXTURE
5	OF THE REVIEW AND GET A SENSE OF WHAT HAPPENED. YOU
6	KNOW, THIS IS SOMETHING I WANT TO TALK TO STAFF
7	ABOUT AND MAKE SURE. IT IS A BURDEN ON STAFF, BUT I
8	THINK IT MAY BE JUST SIMPLY COLLATING THE DIFFERENT
9	PIECES OF INFORMATION THAT THEY HAVE IN FRONT OF
10	THEM INTO A REPORT. SO THAT'S ONE, A REPORT, WHICH
11	IS WHAT I THINK IS WHAT DUANE AND JACOB WERE LOOKING
12	FOR.
13	MR. ROTH: JEFF, I APOLOGIZE. I HAVE TO
14	GO OFF, BUT I THINK THAT MIGHT SOLVE EVEN THE
15	FOLLOW-ON ONES THAT ARE COMING. IF THERE IS A
16	REPORT, THAT MEANS IT HAS TO BE FOCUSED ON BECAUSE
17	YOU HAVE WRITE IT AND THERE HAS TO BE THE
18	DISCUSSION. ANYWAY, I'M GOING TO GET OFF. IS THERE
19	ANOTHER VOTE THAT WE HAVE TO TAKE YOU NEED ME FOR?
20	MS. KING: YES, FOR ITEM NO. 5, WHICH WE
21	COULD PROBABLY DO RELATIVELY QUICKLY.
22	MR. ROTH: SO I'LL HANG ON. I CAN DO
23	ANOTHER FIVE MINUTES OR SO.
24	CHAIRMAN SHEEHY: SO WHAT I'LL DO, I'LL
25	IDENTIFY THESE THREE QUESTIONS. UNLESS SOMEBODY HAS

1	SOMETHING THEY REALLY NEED TO SAY, WE CAN GET OUT.
2	WE'LL MOVE ON.
3	THE SECOND THING TO CONSIDER IS IF THERE
4	ARE SOME CRITERIA THAT MIGHT PROVIDE SOME BASIS FOR
5	AN OBJECTIVE ANALYSIS. AND EVEN IF THEY MAY NOT BE
6	FOR OBJECTIVE ANALYSIS, THEY COULD SERVE AS A
7	DIRECTION TO THE GRANTS WORKING GROUP BEFORE WE
8	START THE MEETING.
9	THE THIRD IS WHAT IS THE DISCUSSION ABOUT
10	THE PROGRAMMATIC ISSUES THAT JOAN AND OS HAVE BEEN
11	TALKING ABOUT THAT SHOULD BE GIVEN TO THE COMMITTEE
12	BEFORE IT STARTS BY DR. SLADEK TO MAKE SURE THAT WE
13	HAVE A FAIRLY UNIFORM SORT OF INSTRUCTIONS.
14	ARE PEOPLE COMFORTABLE WITH THOSE BEING
15	THE THREE AVENUES THAT WE KIND OF CARRY THIS FORWARD
16	FOR FURTHER INFORMATION?
17	CHAIRMAN KLEIN: IN 30 SECONDS, JEFF, WE
18	SHOULD REMIND EVERYONE THAT JAMES HARRISON HAS
19	MATERIALS IN PROGRESS TO RESPOND TO THIS SAME POINT,
20	AND IT RELATES TO YOUR THIRD POINT, I THINK, JEFF,
21	THAT WILL PROVIDE A FORMAL DISCUSSION OF THE ROLES
22	OF THE PATIENT ADVOCATES WITHIN THE PROCESS AND THE
23	ROLES OF STAFF IN SUPPORTING THE PROCESS SO THAT AS
24	WE GO TO IMMUNOLOGY OR DISEASE TEAMS OR, YOU KNOW,
25	TOOLS, WE HAVE DIFFERENT SPECIALIZED GROUPS THAT ARE

1	NOT AS FAMILIAR WITH THE PROCESS, AND THIS WILL HELP
2	THEM UNDERSTAND AND FULLY PARTICIPATE.
3	CHAIRMAN SHEEHY: OKAY. I DON'T THINK WE
4	NEED PUBLIC COMMENT. WE'RE NOT TAKING ACTION. I'M
5	GOING TO GO AHEAD TO ITEM 5.
6	MS. KING: THIS IS AN ITEM THAT HAS BEEN
7	BEFORE THIS SUBCOMMITTEE, A RELATED ITEM AND THEN
8	FOR THE BOARD. AND WHAT THE SUBCOMMITTEE IS LOOKING
9	TO DO AT THIS POINT IS DISCUSS FORMALIZING A
10	PROCESS, GOING A LITTLE BIT FURTHER THAN WHAT WAS
11	VOTED ON BY THE BOARD AT THE BOARD MEETING IN
12	AUGUST.
13	CHAIRMAN SHEEHY: JAMES, COULD YOU RUN US
14	THROUGH THIS QUICKLY?
15	MR. HARRISON: SURE. SO JUST TO BE CLEAR,
16	AS MELISSA SAID, THE BOARD DID VOTE ON A PROCESS OR
17	RATHER AN EXISTING POLICY IN THE GRANTS
18	ADMINISTRATION POLICY RELATING TO THE USE OF UNUSED
19	DISEASE TEAM RESEARCH I AWARD FUNDS AND HUMAN
20	CLINICAL TRIALS. SO THAT'S NOT AT ISSUE HERE.
21	WHAT WE'RE ATTEMPTING TO DISCUSS HERE IS
22	THE BROADER POLICY IMPLICATIONS GOING FORWARD FOR
23	FUTURE AWARD PROGRAMS WHEN AN APPLICANT PROPOSES A
24	CHANGE IN SCOPE OF HIS OR HER RESEARCH PROPOSAL TO
25	INCLUDE RESEARCH INVOLVING CLINICAL RESEARCH
	ζζ

1	INVOLVING HUMANS. SO IT'S LIMITED TO SITUATIONS
2	WHERE HUMAN CLINICAL TRIAL RESEARCH WAS NOT INCLUDED
3	WITHIN THE SCOPE OF THE ORIGINAL APPLICATION, BUT
4	DUE TO THE SUCCESS OF THE RESEARCH, THE APPLICANT
5	HAS LEFT-OVER FUNDS AND WISHES TO CHANGE THE SCOPE
6	OF THE APPLICATION IN ORDER TO USE THOSE FUNDS ON
7	HUMAN CLINICAL RESEARCH.
8	AND THE PROPOSAL UNDER THOSE CIRCUMSTANCES
9	IS TO HAVE THE BOARD APPROVE AT A CONCEPT LEVEL THE
10	REQUEST FOR A CHANGE IN SCOPE TO PERMIT THE USE OF
11	THOSE UNUSED FUNDS FOR HUMAN CLINICAL TRIAL
12	RESEARCH.
13	CHAIRMAN SHEEHY: THANKS, JAMES. AND JUST
14	TO GIVE A CONTEXT, I THINK THAT THERE WERE A LOT OF
15	MEMBERS WITHIN THE LARGER ICOC WHO WERE NOT ABLE TO
16	PARTICIPATE IN THIS DISCUSSION AND FELT THAT A
17	PROCESS WAS NEEDED. SO IF I COULD START WITH A
18	MOTION TO ADOPT.
19	MR. TORRES: SO MOVED.
20	CHAIRMAN SHEEHY: AND A SECOND?
21	CHAIRMAN KLEIN: SECOND.
22	CHAIRMAN SHEEHY: UNLESS PEOPLE REALLY
23	WANT TO GET INTO THE WEEDS ON THIS, I REALLY THINK
24	THIS IS SOMETHING THAT WE SHOULD AT LEAST REFER UP
25	TO THE BOARD GIVEN THE HIGH INTEREST THAT WAS
	F.C.

1	EXPRESSED ON THE BOARD ON SOME SORT OF POLICY FOR
2	THIS.
3	MR. ROTH: JUST QUICKLY, I'LL SUPPORT
4	THAT, TAKE IT TO THE BOARD, BUT I DO NOT THINK THIS
5	IS A NECESSARY CONSIDERATION. I JUST THINK IT'S
6	ADDING ANOTHER LAYER WHERE YOU'VE GOT THE FDA AND
7	THE IRB'S WHO ARE VERY WELL EQUIPPED TO MAKE
8	DECISIONS ABOUT HUMAN CLINICAL TRIALS. I WOULD
9	THINK IT'S NOT NECESSARY, BUT I DO THINK IT SHOULD
10	GO TO THE BOARD FOR MORE DISCUSSION.
11	CHAIRMAN SHEEHY: THAT'S THE MAIN POINT,
12	THAT WE KIND OF PULL TOGETHER A POLICY. PEOPLE MAY
13	HAVE DIFFERENT VIEWS ON HOW WE PULL IT TOGETHER.
14	MS. SAMUELSON: THIS IS JOAN. COULD WE
15	GET STAFF INFORMATION ON HOW MUCH DEMAND THERE HAS
16	BEEN FOR THIS?
17	DR. LEVIN: IT HASN'T HAPPENED YET.
18	CHAIRMAN KLEIN: JUST AS AN EXAMPLE, JOAN,
19	THIS WOULD HAPPEN IF THERE WERE AN EARLY TRANSLATION
20	AWARD, DOESN'T PROPOSE HAVING A HUMAN CLINICAL
21	TRIAL, THERE'S A HUGE BREAKTHROUGH, THERE'S
22	LEFT-OVER FUNDS. VERY RARE SITUATION.
23	MS. SAMUELSON: I JUST WONDERED IF IT'S
24	JUST THEORETICAL. OKAY. ALL RIGHT.
25	MR. ROTH: JEFF, MY VOTE IS YES. THANK
	F 7

	BARRISTERS' REPORTING SERVICE
1	YOU, GUYS.
2	CHAIRMAN SHEEHY: PUBLIC COMMENT? ANY
3	PUBLIC COMMENT IN SAN FRANCISCO? YOU WANT TO CALL
4	THE ROLL, MELISSA.
5	MS. KING: JACOB LEVIN.
6	DR. LEVIN: YES.
7	MS. KING: MICHAEL FRIEDMAN.
8	DR. FRIEDMAN: YES.
9	MS. KING: ROBERT KLEIN.
10	CHAIRMAN KLEIN: YES.
11	MS. KING: JEANNIE FONTANA.
12	DR. FONTANA: YES.
13	MS. KING: WE HAVE DUANE ROTH'S VOTE WHICH
14	IS YES.
15	JOAN SAMUELSON.
16	MS. SAMUELSON: YES.
17	MS. KING: JEFF SHEEHY.
18	CHAIRMAN SHEEHY: YES.
19	MS. KING: OSWALD STEWARD.
20	DR. STEWARD: YES.
21	MS. KING: ART TORRES.
22	MR. TORRES: AYE.
23	MS. KING: AND THAT MOTION CARRIES.
24	CHAIRMAN SHEEHY: OKAY. WE HAVE THE PREAP
25	PROCESS ON HERE TODAY. DO PEOPLE HAVE THE STRENGTH
	58

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	FOR THAT? I KNOW WE'VE BEEN GOING ABOUT AN HOUR AND
2	A HALF.
3	DR. FRIEDMAN: THIS IS MIKE FRIEDMAN. I'M
4	GOING TO NEED TO LEAVE IN ABOUT FOUR MINUTES.
5	CHAIRMAN SHEEHY: A LOT OF PEOPLE HAVE 1
6	O'CLOCKS.
7	MS. SAMUELSON: I THINK IT DESERVES MORE
8	ATTENTION THAN WE HAVE TIME FOR.
9	CHAIRMAN SHEEHY: SO WE CAN DEFER THIS TO
10	THE NEXT MEETING. AND UNLESS ANYONE HAS ANYTHING
11	ELSE THEY'D LIKE TO BRING UP, I THINK THIS HAS BEEN
12	PRODUCTIVE. AND I APPRECIATE EVERYONE'S
13	CONTRIBUTIONS GREATLY.
14	MS. SAMUELSON: THANK YOU, JEFF.
15	CHAIRMAN SHEEHY: THANK YOU VERY MUCH.
16	(THE MEETING WAS ADJOURNED AT 12:51
17	P.M.)
18	
19	
20	
21	
22	
23	
24	
25	
	50

## REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE SCIENCE SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING ON WEDNESDAY, SEPTEMBER 29, 2010, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 BRISTOL STREET SUITE 100 COSTA MESA, CALIFORNIA (714) 444-4100